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ABSTRACT	1	
To	dissect	the	genetic	architecture	of	blood	pressure	and	assess	effects	on	target-organ	damage,	2	
we	analyzed	128,272	SNPs	from	targeted	and	genome-wide	arrays	in	201,529	individuals	of	European	3	
ancestry	and	genotypes	from	an	additional	140,886	individuals	were	used	for	validation.	We	identified	4	
66	blood	pressure	loci,	of	which	17	were	novel	and	15	harbored	multiple	distinct	association	signals.		5	
The	66	index	SNPs	were	enriched	for	cis-regulatory	elements,	particularly	in	vascular	endothelial	cells,	6	
consistent	with	a	primary	role	in	blood	pressure	control	through	modulation	of	vascular	tone	across	7	
multiple	tissues.		The	66	index	SNPs	combined	in	a	risk	score	showed	comparable	effects	in	64,421	8	
individuals	of	non-European	descent.		The	66-SNP	blood	pressure	risk	score	was	significantly	associated	9	
with	target-organ	damage	in	multiple	tissues,	with	minor	effects	in	the	kidney.	Our	findings	expand	10	
current	knowledge	of	blood	pressure	pathways	and	highlight	tissues	beyond	the	classic	renal	system	in	11	
blood	pressure	regulation.	 	12	
	15	
INTRODUCTION	1	
There	are	considerable	physiological,	clinical	and	genetic	data	that	point	to	the	kidney	as	the	2	
major	regulator	of	blood	pressure	(BP)	and	to	renal	damage	as	a	consequence	of	long-term	BP	elevation.		3	
However,	alternative	hypotheses,	such	as	increasing	systemic	vascular	resistance,	are	also	serious	4	
contenders	to	explain	the	rise	of	BP	with	increasing	age,	but	with	limited	genetic	support.	The	genetic	5	
basis	of	elevated	blood	pressure	or	hypertension	(HTN)	involves	many	loci	that	have	been	identified	6	
using	large-scale	analyses	of	candidate	genes1,2,	linkage	studies,	and	genome-wide	association	studies	7	
(GWAS)3-12.		The	genes	underlying	BP	regulation	can	help	resolve	many	of	the	open	questions	regarding	8	
BP	(patho-)	physiology.		While	~40-50%	of	BP	variability	is	heritable13,14,	the	genetic	variation	identified	9	
to	date	explains	only	~2%1-12.	10	
The	Cardio-MetaboChip	is	a	custom	genotyping	microarray	designed	to	facilitate	cost-effective	11	
follow-up	of	nominal	associations	for	metabolic	and	cardiovascular	traits,	including	BP.		This	array	12	
comprises	196,725	variants,	including	~5,000	SNPs	with	nominal	(P	<0.016)	evidence	of	BP	association	in	13	
our	previous	GWAS	meta-analysis5.		Furthermore,	the	array	includes	several	dense	scaffolds	for	fine	14	
mapping	of	selected	loci	spanning,	on	average,	genomic	regions	of	350	kilobases5,16,	of	which	24	include	15	
genome-wide	significant	BP	association	in	the	current	study5,16.	16	
RESULTS	17	
Novel	genetic	loci	associated	with	systolic	and	diastolic	BP	18	
	 We	performed	meta-analyses	of	association	summary	statistics	from	a	total	of	201,529	19	
individuals	of	European	(EUR)	ancestry	from	74	studies:	(i)	109,096	individuals	from	46	studies	20	
genotyped	on	Cardio-MetaboChip;	and	(ii)	92,433	individuals	from	28	studies	with	imputed	genotype	21	
data	from	genome-wide	genotyping	at	variants	included	on	the	Cardio-MetaboChip.	Twenty-four	of	the	22	
28	studies	with	genome-wide	genotyping	data	had	contributed	to	previous	analyses	(Supplementary	23	
Tables	1-3)5,7.	24	
BP	was	measured	using	standardized	protocols	in	all	studies5,17	(Supplementary	Table	1,	Online	25	
methods).	Association	statistics	for	systolic	and	diastolic	BP	(SBP	and	DBP)	in	models	adjusting	for	age,	26	
age2,	sex,	and	body	mass	index	(BMI),	were	obtained	for	each	study	separately,	with	study-specific	27	
genomic	control	applied	to	correct	for	possible	population	structure.		Fixed-effects	meta-analysis	28	
proceeded	in	4	stages,	separately	for	the	following	SNP	associations:	Stage	1,	using	results	based	on	46	29	
studies	using	Cardio-MetaboChip	genotypes	of	109,096	participants;	Stage	2,	using	additional	results	30	
based	on	imputed	genotypes	from	genome-wide	genotyping	arrays	in	4	previously	unpublished	studies;	31	
	16	
Stage	3	using	imputed	genotypes	from	genome-wide	genotyping	arrays	in	24	previously	published	1	
studies5;	and	Stage	4,		the	joint	meta-analysis	of	Stages	1-3	including	a	total	of	201,529	independent	2	
individuals	(Supplementary	Figure	1,	Supplementary	Tables	2-3,	Supplementary	Note).	To	account	for	3	
population	structure	between	studies	in	Stages	1-3	of	our	meta-analysis,	genomic	control	correction	was	4	
applied	to	meta-analysis	results	from	each	of	these	stages	in	an	approach	aggregating	summary	5	
statistics	from	GWAS	and	Cardio-MetaboChip	studies18,19.	6	
After	stage	4,	67	loci	attained	genome-wide	significance	(P	<	5	x	10-8),	18	of	which	were	not	7	
previously	reported	in	the	literature	(Supplementary	Table	4).	Quantile-quantile	plots		of	the	stage	4	8	
meta-analysis	showed	an	excess	of	small	P	values,	with	an	elevated	genomic	control	lambda	estimate	9	
that	was	persistent,	albeit	attenuated,	after	excluding	all	66	loci	(Supplementary	Figure	2).		This	10	
observation	is	compatible	with	either	residual	uncorrected	population	stratification	or	the	presence	of	a	11	
large	number	of	variants	that	are	truly	associated	with	BP	but	fail	to	achieve	genome-wide	significance	12	
in	the	current	meta-analysis.		The	Cardio-MetaboChip	array’s	inclusion	of	SNPs	from	a	prior	BP	GWAS5	13	
does	not	appear	to	be	the	sole	explanation,	as	we	did	not	observe	a	significant	decrease	of	the	excess	of	14	
small	P	values	after	exclusion	of	all	SNPs	that	were	included	on	the	Cardio-MetaboChip	based	on	15	
nominal	BP	association	(Supplementary	Figures	3	and	4).		Since	the	quantile-quantile	plots	continued	to	16	
show	deviation	from	the	null	expectation,	we	sought	additional	validation	for	18	variants	attaining	17	
genome-wide	significance,	but	without	prior	support	in	the	literature,	in	up	to	140,886	individuals	of	18	
European	ancestry	from	UK	Biobank20.		For	these	SNPs,	we	performed	a	stage	5	meta-analysis	combining	19	
the	association	summary	statistics	from	stage	4	and	UK	Biobank,	in	a	total	of	up	to	342,415	individuals	20	
(Supplementary	Table	5).	21	
Upon	stage	5	meta-analysis,	17	of	18	variants	retained	genome-wide	significance	for	the	primary	22	
trait	(SBP	or	DBP	result	with	the	lower	P	value).		The	one	variant	that	was	not	genome-wide	significant	23	
had	a	borderline	P	value	of	4.49	x	10-8	at	stage	4.		These	findings	are	consistent	with	appropriate	24	
calibration	of	the	association	test	statistics	at	stage	4	such	that	observing	one	failure	among	18	25	
validation	tests	is	consistent	with	the	use	of	a	threshold	(P	<	5	x	10-8)	designed	to	have	a	1	in	20	chance	26	
of	a	result	as	or	more	extreme	solely	due	to	chance.		In	total,	66	loci	attained	genome-wide	significance:	27	
13	loci	for	SBP	only,	12	loci	for	DBP	only,	and	41	loci	for	both	traits.	Of	these,	17	BP	loci	were	novel,	28	
while	49	were	previously	reported	at	genome-wide	significance	(Table	1	and	Figure	1).	29	
Compared	with	previously	reported	BP	variants5,7,21,	the	average	absolute	effect	size	of	the	30	
newly	discovered	variants	is	smaller,	with	comparable	minor	allele	frequency	(MAF),	presumably	owing	31	
to	the	increased	power	of	a	larger	sample	size	(Table	2).		As	expected	from	the	high	correlation	between	32	
	17	
SBP	and	DBP	effects,	the	observed	directions	of	effects	for	the	two	traits	were	generally	concordant	1	
(Supplementary	Figure	5),	and	the	absolute	effect	sizes	were	inversely	correlated	with	MAF	(Table	1	2	
and	Supplementary	Figure	6).	The	66	BP	SNPs	explained	3.46%	and	3.36%	of	SBP	and	DBP	variance,	3	
respectively,	a	modest	increase	from	2.95%	and	2.78%	for	SBP	and	DBP,	respectively,	for	the	49	4	
previously	reported	SNPs	(Supplementary	Note).	The	low	percent	variance	explained	is	consistent	with	5	
estimates	that	large	numbers	of	common	variants	with	weak	effects	at	a	large	number	of	loci	influence	6	
BP5.	7	
Signal	refinement	at	the	66	BP	loci	8	
To	identify	distinct	signals	of	association	at	the	66	BP	loci	and	the	variants	most	likely	to	be	9	
causal	for	each,	we	started	with	an	approximate	conditional	analysis	using	a	model	selection	procedure	10	
implemented	in	the	GCTA-COJO	package22,23	as	well	as	a	detailed	literature	review	of	all	published	BP	11	
association	studies.		GCTA-COJO	analysis	was	performed	using	the	association	summary	statistics	for	SBP	12	
and	DBP	from	the	Stage	4	EUR	ancestry	meta-analyses,	with	the	linkage	disequilibrium	(LD)	between	13	
variants	estimated	on	the	basis	of	Cardio-MetaboChip	genotype	data	from	7,006	individuals	of	EUR	14	
ancestry	from	the	GoDARTS	cohort24.		More	than	one	distinct	BP	association	signal	was	identified	at	13	15	
loci	at	P	<	5	x	10-8	(Supplementary	Table	6,	Supplementary	Figures	7,	and	Supplementary	Note).		At	six	16	
loci,	the	distinct	signals	were	identified	for	both	SBP	and	DBP	analyzed	separately;	these	trait-specific	17	
associations	were	represented	by	the	same	or	highly	correlated	(r2	>	0.8)	SNPs	at	5	of	the	6	loci	18	
(Supplementary	Tables	7	and	8).		We	repeated	GCTA-COJO	analyses	using	the	same	summary	19	
association	results,	but	with	a	different	reference	sample	for	LD	estimates	(WTCCC1-T2D/58BC,	N	=	20	
2,947,	Supplementary	Note)	and	observed	minimal	differences	arising	from	minor	fluctuations	in	the	21	
association	P	value	in	the	joint	regression	models	(Supplementary	Tables	7	and	8).		LD-based	22	
comparisons	of	published	association	signals	at	established	BP	loci,	and	the	current	study’s	findings	23	
suggested	that	at	10	loci,	the	signals	identified	by	the	single-SNP	and	the	GCTA-COJO	analyses	were	24	
distinct	from	those	reported	in	the	literature	(Supplementary	Table	9).	25	
We	then	performed	multivariable	regression	modeling	in	a	single	large	cohort	(Women’s	26	
Genome	Health	Study,	WGHS,	N	=	23,047)	with	simultaneous	adjustment	for	both	1)	all	combinations	of	27	
putative	index	SNPs	for	each	distinct	signal	from	the	GCTA-COJO	conditional	analyses,	and	2)	all	index	28	
SNPs	for	all	potential	distinct	signals	identified	by	our	literature	review	(Supplementary	Table	9,	29	
Supplementary	Note).		Although	WGHS	is	very	large	as	a	single	study,	power	is	reduced	in	a	single	30	
sample	compared	to	that	in	the	overall	meta-analysis	(23k	vs.	342k	individuals)	and	consequently	the	31	
	18	
failure	to	reach	significance	does	not	represent	non-replication	for	individual	SNPs.		The	WGHS	analysis	1	
supported	two	distinct	association	signals	at	eight	of	13	loci	identified	in	the	GCTA-COJO	analysis,	but	2	
could	not	provide	support	for	the	remaining	five	(Supplementary	Table	10).		The	joint	SNP	modeling	in	3	
WGHS	additionally	supported	two	distinct	signals	of	association	at	three	other	loci	(GUCY1A3-GUCY1B3,	4	
SYNPO2L	and	TBX5-TBX3),	at	which	the	SNP	identified	in	the	current	study	is	distinct	from	that	5	
previously	reported	in	the	literature5,11.	6	
	 We	sought	to	refine	the	localization	of	likely	functional	variants	at	loci	with	high-density	7	
coverage	on	the	Cardio-MetaboChip.	We	followed	a	Bayesian	approach	to	define,	for	each	signal,	8	
credible	sets	of	variants	that	have	99%	probability	of	containing	or	tagging	the	causal	variant	9	
(Supplementary	Note).		To	improve	the	resolution	of	the	method,	the	analyses	were	restricted	to	24	10	
regions	selected	to	fine	map	(FM)	genetic	associations,	and	that	included	at	least	one	SNP	reaching	11	
genome-wide	significance	in	the	current	meta-analyses	(Supplementary	Table	11).		Twenty-one	of	the	12	
Cardio-MetaboChip	FM	regions	were	BP	loci	in	the	original	design,	with	three	of	the	newly	discovered	13	
BP	loci	in	FM	regions	that	were	originally	selected	for	other	non-BP	traits.		We	observed	that	the	99%	14	
credible	SNP	sets	at	five	BP	loci	spanned	<20kb.		The	greatest	refinement	was	observed	at	the	SLC39A8	15	
locus	for	SBP	and	DBP,	and	at	the	ZC3HC1	and	PLCE1	loci	for	DBP,	where	the	99%	credible	sets	included	16	
only	the	index	variants	(Supplementary	Table	12).	Although	SNPs	in	credible	sets	were	primarily	non-17	
coding,	they	included	one	synonymous	and	seven	non-synonymous	variants	that	attained	high	posterior	18	
probability	of	driving	seven	distinct	association	signals	at	six	BP	loci	(Supplementary	Table	12).		Of	19	
these,	three	variants	alone	account	for	more	than	95%	of	the	posterior	probability	of	driving	the	20	
association	signal	observed	at	each	of	three	loci	(Supplementary	Table	12	and	13).	Despite	reduced	21	
statistical	power,	the	analyses	restricted	to	the	samples	with	Cardio-MetaboChip	genotypes	only	22	
(N	=	109,096)	identified	the	majority	of	SNPs	identified	in	the	GWAS+Cardio-MetaboChip	data	23	
(Supplementary	Table	12).	The	full	list	of	SNPs	in	the	99%	credible	sets	are	listed	in	Supplementary	24	
Table	13.	25	
What	do	the	BP	variants	do?	26	
Index	SNPs	or	their	proxies	(r2	>	0.8)	altered	amino	acid	sequence	at	11	of	66	BP	loci	(Table	1).		27	
Thus,	the	majority	of	BP-association	signals	are	likely	driven	by	non-coding	variants	hypothesized	to	28	
regulate	expression	of	some	nearby	gene	in	cis.		To	characterize	their	effects,	we	first	sought	SNPs	29	
associated	with	gene	expression	(eSNPs)	from	a	range	of	available	expression	data	which	included	30	
hypertension	target	end	organs	and	cells	of	the	circulatory	system	(heart	tissue,	kidney	tissue,	brain	31	
	19	
tissue,	aortic	endothelial	cells,	blood	vessels)	and	other	tissue/cell	types	(CD4+	macrophages,	monocytes	1	
lymphoblastoid	cell	lines,	skin	tissue,	fat	tissue,	and	liver	tissue).		Fourteen	BP-associated	SNPs	at	the	2	
MTHFR-NPPB,	MDM4,	ULK4,	CYP1A1-ULK3,	ADM,	FURIN-FES,	FIGN,	and	PSMD5	loci	were	eSNPs	across	3	
different	tissues	(Supplementary	Table	14).		Of	these	14	eSNPs,	three	were	also	predicted	to	alter	the	4	
amino	acid	sequence	at	the	MTHFR-NPPB,	MAP4	and	ULK4	loci,	providing	two	potential	mechanisms	to	5	
explore	in	functional	studies.		Second,	we	used	gene	expression	levels	measured	in	whole	blood	in	two	6	
different	samples	each	including	>5,000	individuals	of	EUR	descent.		We	tested	whether	the	lead	BP	SNP	7	
was	associated	with	expression	of	any	transcript	in	cis	(<1Mb	from	the	lead	SNP	at	each	locus)	at	a	false	8	
discovery	rate	(FDR)	of	<	0.05,	accounting	for	all	possible	cis-transcript	association	tests	genome-wide.		9	
It	is	likely	that	we	did	not	genotype	the	causal	genetic	variant	underlying	each	BP	association	signal;	a	10	
nearby	SNP-transcript	association,	due	to	LD,	may	therefore	reflect	an	independent	genetic	effect	on	11	
expression	that	is	unrelated	to	the	BP	effect.		Consequently,	we	assumed	that	the	lead	BP	SNP	and	the	12	
most	significant	eSNP	for	a	given	transcript	should	be	highly	correlated	(r2	>	0.7).		Furthermore,	we	13	
assumed	that	the	significance	of	the	transcript	association	with	the	lead	BP	SNP	should	be	substantially	14	
reduced	in	a	conditional	model	adjusting	for	the	best	eSNP	for	a	given	transcript.		Eighteen	SNPs	at	15	15	
loci	were	associated	with	22	different	transcripts,	with	a	total	of	23	independent	SNP-transcript	16	
associations	(three	SNPs	were	associated	with	two	transcripts	each,	Supplementary	Table	15,	17	
Supplementary	Note).		The	genes	expressed	in	a	BP	SNP	allele-specific	manner	are	clearly	high-priority	18	
candidates	to	mediate	the	BP	association.		In	whole	blood,	these	genes	included	obvious	biological	19	
candidates	such	as	GUCY1A3,	encoding	the	alpha	subunit	of	the	soluble	guanylate	cyclase	protein,	and	20	
ADM,	encoding	adrenomedullin,	both	of	which	are	known	to	induce	vasodilation25,26.	There	was	some	21	
overlap	of	eSNPs	between	the	whole	blood	and	other	tissue	datasets	at	the	MTHFR-NPPB,	MDM4,	22	
PSMD5,	ULK4	and	CYP1A1-ULK3	loci,	illustrating	additional	potentially	causal	genes	for	further	study.	23	
An	alternative	method	for	understanding	the	effect	on	BP	of	non-coding	variants	is	to	determine	24	
whether	they	fall	within	DNaseI	hypersensitivity	sites	(DHSs).	We	performed	two	analyses	to	investigate	25	
whether	BP	SNPs	or	their	LD	proxies	(r2	>	0.8)	were	enriched	in	DHSs	in	a	cell-type-specific	manner	26	
(Supplementary	Note).		First,	we	used	Epigenomics	Roadmap	and	ENCODE	DHS	data	from	123	adult	cell	27	
lines	or	tissues27-29	to	estimate	the	fold	increase	in	the	proportion	of	BP	SNPs	mapping	to	DHSs	28	
compared	to	SNPs	associated	at	genome-wide	significance	with	non-BP	phenotypes	from	the	NHGRI	29	
GWAS	catalog30.		We	observed	that	7	out	of	the	10	cell	types	with	the	greatest	relative	enrichment	of	BP	30	
SNPs	mapping	to	DHSs	were	from	blood	vessels	(vascular	or	micro-vascular	endothelial	cell-lines	or	cells)	31	
and	11	of	the	12	endothelial	cells	were	among	the	top	quarter	most	enriched	among	the	123	cell	types	32	
	20	
(Figure	2	and	Supplementary	Table	16).		In	a	second	analysis	of	an	expanded	set	of	tissues	and	cell	lines,	1	
in	which	cell	types	were	grouped	into	tissues	(Supplementary	Table	17),	BP-associated	SNP	enrichment	2	
in	DHSs	in	blood	vessels	was	again	observed	(P	=	1.2	x	10-9),	as	well	as	in	heart	samples	(P	=	5.3	x	10-8;	3	
Supplementary	Table	18).	4	
We	next	tested	whether	there	was	enrichment	of	BP	SNPs	in	H3K4me331	sites,	a	methylation	5	
mark	associated	with	both	promoter	and	enhancer	DNA.	We	observed	significant	enrichment	in	a	range	6	
of	cell	types	including	CD34	primary	cells,	adult	kidney	cells,	and	muscle	satellite	cultured	cells	7	
(Supplementary	Table	19).		Enrichment	of	BP	SNPs	in	predicted	strong	and	weak	enhancer	states	and	in	8	
active	promoters32	in	a	range	of	cell	types	was	also	observed	(Supplementary	Table	20,	Supplementary	9	
Figure	8).	10	
We	used	Meta-Analysis	Gene-set	Enrichment	of	variaNT	Associations	(MAGENTA)33	to	attempt	11	
to	identify	pathways	over-represented	in	the	BP	association	results.		No	gene	sets	meeting	experiment-12	
wide	significance	for	enrichment	for	BP	association	were	identified	by	MAGENTA	after	correction	for	13	
multiple	testing,	although	some	attained	nominal	significance	(Supplementary	Table	21,	Supplementary	14	
Note).		We	also	adapted	the	DEPICT34	pathway	analysis	tool	(Data-driven	Expression	Prioritized	15	
Integration	for	Complex	Traits)	to	identify	assembled	gene-sets	that	are	enriched	for	genes	near	16	
associated	variants,	and	to	assess	whether	genes	from	associated	loci	were	highly	expressed	in	17	
particular	tissues	or	cell	types.		Using	the	extended	BP	locus	list	based	on	genome-wide	significant	loci	18	
from	this	analysis	and	previously	published	SNPs	that	may	not	have	reached	genome-wide	significance	19	
in	the	current	analysis	(Supplementary	Table	9),	we	identified	five	significant	(FDR	≤	5%)	gene	sets:	20	
abnormal	cardiovascular	system	physiology,	G	Alpha	1213	signaling	events,	embryonic	growth	21	
retardation,	prolonged	QT	interval,	and	abnormal	vitelline	vasculature	morphology.		We	also	found	that	22	
suggestive	SBP	and	DBP	associations	(P	<	1	x	10-5)	were	enriched	for	reconstituted	gene-sets	at	DBP	loci	23	
(mainly	related	to	developmental	pathways),	but	not	at	SBP	loci	(Supplementary	Table	22,	24	
Supplementary	Note).		In	a	final	analysis,	we	assessed	Cardio-MetaboChip	SNPs	at	the	fine-mapping	loci	25	
using	formaldehyde-assisted	isolation	of	regulatory	elements	(FAIRE-gen)	in	lymphoblastoid	cell	lines35.		26	
Our	results	provided	support	for	two	SNPs,	one	of	which	SNP	(rs7961796	at	the	TBX5-TBX3	locus)	was	27	
located	in	a	regulatory	site.		Although	the	other	SNP	(rs3184504	at	the	SH2B3	locus)	is	a	non-28	
synonymous	variant,	there	was	also	a	regulatory	site	indicated	by	DNaseI	and	H3K4me1	signatures	at	29	
the	locus,	making	the	SNP	a	potential	regulatory	variant	(Supplementary	Table	23)36.		Both	SNPs	were	30	
included	in	the	list	of	99%	credible	SNPs	at	each	locus.	31	
	21	
Asian-	and	African	ancestry	BP	SNP	association	1	
We	tested	the	66	lead	SNPs	at	the	established	and	novel	loci	for	association	with	BP	in	up	to	2	
20,875	individuals	of	South	Asian	(SAS)	ancestry	(PROMIS	and	RACE	studies),	9,637	individuals	of	East	3	
Asian	(EAS)	ancestry	(HEXA,	HALST,	CLHNS,	DRAGON,	and	TUDR	studies),	and	33,909	individuals	of	4	
African	(AFR)	ancestry	(COGENT-BP	consortium,	Jupiter,	SPT,	Seychelles,	GXE,	and	TANDEM	studies).		As	5	
expected,	the	effect	allele	frequencies	are	very	similar	across	studies	of	the	same	ethnicity,	but	6	
markedly	different	across	different	ancestry	groups	(Supplementary	Figure	9).		Many	associations	of	7	
individual	SNPs	failed	to	reach	P	<	0.05	for	the	BP	trait	with	the	lower	P	value	(Supplementary	Table	24),	8	
which	could	potentially	be	due	to	the	much	lower	statistical	power	at	the	sample	sizes	available,	9	
different	patterns	of	LD	at	each	locus	across	ancestries,	variability	in	allele	frequency,	or	true	lack	of	10	
association	in	individuals	of	a	given	non-European	ancestry.		The	low	statistical	power	for	the	great	11	
majority	of	SNPs	tested	is	visible	considering	SNP-by-SNP	power	calculations	using	European	ancestry	12	
effect	sizes	(Supplementary	Table	24).		However,	concordant	directions	of	allelic	effects	for	both	SBP	13	
and	DBP	were	observed	for	45/66	SNPs	in	SAS,	36/60	SNPs	in	EAS,	and	42/66	SNPs	in	AFR	samples:	the	14	
strongest	concordance	with	SAS	may	not	be	surprising	because	South	Asians	are	more	closely	related	to	15	
Europeans	than	are	East	Asians	or	Africans.		Moreover,	strong	correlation	of	effect	sizes	was	observed	16	
between	EUR	samples	with	SAS,	EAS,	or	AFR	samples	(r	=	0.55,	0.60,	and	0.48,	respectively).	A	66-SNP	17	
SBP	or	DBP	risk	score	were	significant	predictors	of	SBP	and	DBP	in	all	samples.	A	1	mm	Hg	higher	SBP	or	18	
DBP	risk	score	in	EUR	samples	was	associated	with	a	0.58/0.50	mm	Hg	higher	SBP/DBP	in	SAS	samples	19	
(SBP	P	=	1.5	x	10-19,	DBP	P	=	3.2	x	10-15),	0.49/0.50	mm	Hg	higher	SBP/DBP	in	EAS	samples	(SBP	20	
P	=	1.9	x	10-10,	DBP	P	=	1.3	x	10-7),	and	0.51/0.47	mm	Hg	higher	SBP/DBP	in	AFR	samples	(SBP	21	
P	=	2.2	x	10-21,	DBP	P	=	6.5	x	10-19).		The	attenuation	of	the	genetic	risk	score	estimates	in	non-European	22	
ancestries	is	presumably	due	to	inclusion	of	a	subset	of	variants	that	lack	association	in	the	non-23	
European	or	admixed	samples.	24	
We	subsequently	performed	a	trans-ethnic	meta-analysis	of	the	66	SNPs	in	all	64,421	samples	25	
across	the	three	non-European	ancestries.		After	correcting	for	66	tests,	12/66	SNPs	were	significantly	26	
associated	with	either	SBP	or	DBP	(P	<	7.6	x	10-4),	with	a	correlation	of	EUR	and	non-EUR	effect	27	
estimates	of	0.77	for	SBP	and	0.67	for	DBP;	the	European-ancestry	SBP	or	DBP	risk	score	was	associated	28	
with	0.53/0.48	mm	Hg	higher	BP	per	predicted	mm	Hg	SBP/DBP	respectively	(SBP	P	<	6.6	x	10-48,	DBP	29	
P	<	1.3	x	10-38).		For	7	of	the	12	significant	SNPs,	no	association	has	previously	been	reported	in	genome-30	
wide	studies	of	non-European	ancestry.		Some	heterogeneity	of	effects	was	observed	between	31	
European	and	non-European	effect	estimates	(Supplementary	Table	24).		Taken	together,	these	findings	32	
	22	
suggest	that,	in	aggregate,	BP	loci	identified	using	data	from	individuals	of	EUR	ancestry	are	also	1	
predictive	of	BP	in	non-EUR	samples,	but	larger	non-European	sample	sizes	will	be	needed	to	establish	2	
precisely	which	individual	SNPs	are	associated	in	a	given	ethnic	group.	3	
Impact	on	hypertensive	target	organ	damage	4	
Long-term	elevated	BP	causes	target	organ	damage,	especially	in	the	heart,	kidney,	brain,	large	5	
blood	vessels,	and	the	retinal	vessels37.		Consequently,	the	genetic	effect	of	the	66	SBP	and	DBP	SNPs	on	6	
end-organ	outcomes	can	be	directly	tested	using	the	risk	score,	although	some	outcomes	lacked	results	7	
for	a	small	number	of	SNPs.		Interestingly,	BP	risk	scores	significantly	predicted	(Supplementary	Note)	8	
coronary	artery	disease	risk,	left	ventricular	mass	and	wall	thickness,	stroke,	urinary	albumin/creatinine	9	
ratio,	carotid	intima-medial	thickness	and	central	retinal	artery	caliber,	but	not	heart	failure	or	other	10	
kidney	phenotypes,	after	accounting	for	the	number	of	outcomes	examined	(Table	3).	Because	outlier	11	
effects	can	affect	risk	scores,	we	repeated	the	risk	score	analysis	removing	iteratively	SNPs	that	12	
contributed	to	statistical	heterogeneity	(SNP-trait	effects	relative	to	SNP-BP	effects).	Heterogeneity	was	13	
defined	based	on	a	multiple	testing	adjusted	significance	threshold	for	Cochran’s	Q	test	of	homogeneity	14	
of	effects	(Supplementary	Note).		The	risk	score	analyses	restricted	to	the	subset	of	SNPs	showing	no	15	
heterogeneity	of	effect	revealed	essentially	identical	results,	with	the	exception	that	urinary	16	
albumin/creatinine	ratio	was	no	longer	significant.		The	per-SNP	results	are	provided	in	Supplementary	17	
Table	25	and	Supplementary	Figures	10.		Because	large-scale	GWAS	of	non-BP	cardiovascular	risk	18	
factors	are	available,	we	examined	the	BP	risk	scores	as	predictors	of	other	cardiovascular	risk	factors:	19	
LDL-cholesterol,	HDL-cholesterol,	triglycerides,	type	2	diabetes,	BMI,	and	height.	We	observed	nominal	20	
(P	<0.05)	associations	of	the	BP	risk	scores	with	risk	factors,	although	mostly	in	the	opposite	direction	to	21	
the	risk	factor-CVD	association	(Supplementary	Table	26).		The	failure	to	demonstrate	an	effect	of	BP	22	
risk	scores	on	heart	failure	may	reflect	limited	power	from	a	modest	sample	size,	but	the	lack	of	23	
significant	effects	on	renal	measures	suggests	that	the	epidemiologic	relationship	of	higher	BP	and	24	
worse	renal	function	may	not	reflect	direct	consequences	of	BP	elevation.	25	
DISCUSSION	26	
The	study	reported	here	is	the	largest	to	date	to	investigate	the	genomics	of	BP	in	multiple	27	
continental	ancestries.		Our	results	highlight	four	major	features	of	inter-individual	variation	in	BP:	(1)	28	
we	identified	66	(17	novel)	genome-wide	significant	loci	for	SBP	and	DBP	by	targeted	genotyping	in	up	29	
to	342,415	individuals	of	European	ancestry	that	cumulatively	explain	~3.5%	of	the	trait;	(2)	the	variants	30	
were	enriched	for	cis-regulatory	elements,	particularly	in	vascular	endothelial	cells;	(3)	the	variants	had	31	
	23	
broadly	comparable	BP	effects	in	South	Asians,	East	Asian	and	Africans,	albeit	in	smaller	sample	sizes;	1	
and,	(4)	a	66	SNP	risk-score	predicted	target	organ	damage	in	the	heart,	cerebral	vessels,	carotid	artery	2	
and	the	eye	with	little	evidence	for	an	effect	in	kidneys.		Overall,	there	was	no	enrichment	of	a	single	3	
genetic	pathway	in	our	data;	rather,	our	results	are	consistent	with	the	effects	of	BP	arising	from	4	
multiple	tissues	and	organs.	5	
Genetic	and	molecular	analyses	of	Mendelian	syndromes	of	hypertension	and	hypotension	point	6	
largely	to	a	renal	origin,	involving	multiple	rare	deleterious	mutations	in	proteins	that	regulate	salt-7	
water	balance38.	This	is	strong	support	for	Guyton’s	hypothesis	that	the	regulation	of	sodium	excretion	8	
by	the	kidney	and	its	effects	on	extracellular	volume	are	a	prime	pathway	determining	intra-arterial	9	
pressure39.		However,	our	genetic	data	from	unselected	individuals	in	the	general	community	argues	10	
against	a	single	dominant	renal	effect.	The	66	SNPs	we	identified	are	not	chance	effects,	but	have	a	11	
global	distribution	and	impact	on	BP	that	are	consistent	as	measured	by	their	effects	across	the	many	12	
studies	meta-analyzed.		That	they	are	polymorphic	across	all	continental	ancestries	argues	for	their	13	
origin	and	functional	effects	prior	to	human	continental	differentiation.	14	
However	several	of	the	17	novel	loci	contain	strong	positional	biological	candidates,	these	are	15	
described	in	greater	detail	in	Supplementary	Table	27	and	the	Supplementary	Note.	The	single	most	16	
common	feature	we	identified	was	the	enrichment	of	regulatory	elements	for	gene	expression	in	17	
vascular	endothelial	cells.		The	broad	distribution	of	these	cells	across	both	large	and	small	vessels	and	18	
across	all	tissues	and	organs	suggest	that	functional	variation	in	these	cells	affects	endothelial	19	
permeability	or	vascular	smooth	muscle	cell	contractility	via	multiple	pathways.	These	hypotheses	will	20	
need	to	be	rigorously	tested	in	appropriate	models,	to	assess	the	contribution	of	these	pathways	to	BP	21	
control,	and	these	pathways	could	also	be	targets	for	systemic	anti-hypertensive	therapy	as	they	are	for	22	
the	pulmonary	circulation42.	23	
In	summary,	these	genetic	observations	may	contribute	to	an	improved	understanding	of	BP	24	
biology	and	a	re-evaluation	of	the	pathways	considered	relevant	for	therapeutic	BP	control.25	
	24	
SUPPLEMENTARY	NOTE	1	
Supplementary	Note	is	available	in	the	online	version	of	the	paper.	2	
SUMMARY	STATISTICS	3	
Full	summary	statistics	(P	values)	are	in	the	online	version	of	the	paper	(file	“ICBPCMfinalMeta.csv.zip”).	4	
URLs	5	
http://hgdownload.cse.ucsc.edu/goldenPath/hg19/encodeDCC/wgEncodeUwDnase	for	enrichment	6	
analyses.	Accessed	3/13/2013.	7	
http://www.genome.gov/gwastudies	for	enrichment	analyses.	Accessed	3/13/2013.	8	
http://genome.ucsc.edu/ENCODE/cellTypes.html	for	enrichment	analyses.		Accessed	3/13/2013.	9	
ACKNOWLEDGEMENTS	10	
We	 thank	 all	 the	 study	participants	 of	 this	 study	 for	 their	 contributions.	Detailed	 acknowledgment	 of	11	
funding	sources	is	provided	in	the	Supplementary	Note.	12	
AUTHOR	CONTRIBUTIONS	13	
Analysis	group	14	
Design	of	secondary	analyses:	G.B.E.,	T.Ferreira,	T.J.,	A.P.M.,	P.B.M.,	C.N.-C.	Computation	of	secondary	15	
analyses:	G.B.E.,	T.Ferreira,	T.J.,	A.P.M.,	P.B.M.,	C.N.-C.	Paper	writing:	A.C.,	G.B.E.,	T.Ferreira,	T.J.,	A.P.M.,	16	
P.B.M.,	C.N.-C.	Study	management:	P.B.M.,	C.N.-C.	17	
Cardio-MetaboChip	or	new	GWAS		18	
WGHS:	Study	phenotyping:	P.M.R.,	D.I.C.,	L.M.R.		Genotyping	or	analysis:	P.M.R.,	D.I.C.,	L.M.R.,	19	
F.Giulianini		Study	PI:	P.M.R.			20	
JUPITER:	Study	phenotyping:	P.M.R.,	D.I.C.,	L.M.R.		Genotyping	or	analysis:	D.I.C.,	L.M.R.,	F.Giulianini		21	
Study	PI:	P.M.R.,	D.I.C.			22	
deCODE:		Study	phenotyping:	G.B.		Genotyping	or	analysis:	G.T.		Study	PI:	K.S.,	U.T.			23	
GoDARTS:	Study	phenotyping:	C.N.A.P.,	L.A.D.,	A.D.M.,	A.S.F.D.		Genotyping	or	analysis:	C.N.A.P.,	L.A.D.,	24	
A.D.M.,	M.I.M.,	C.G.,	N.W.W.R.R.		Study	PI:	C.N.A.P.,	A.D.M.			25	
KORA	F3/F4:	Study	phenotyping:	A.D.,	H.Schunkert,	J.E.		Genotyping	or	analysis:	A.-K.P.,	M.M.-N.,	N.K.,	26	
T.I.		Study	PI:	H.-E.W.,	A.Peters			27	
GLACIER:	Study	phenotyping:	F.R.,	G.H.		Genotyping	or	analysis:	P.W.F.,	D.Shungin,	I.B.,	S.Edkins,	F.R.		28	
Study	PI:	P.W.F.			29	
B58C:	Genotyping	or	analysis:	S.Kanoni,	K.E.S.,	Wellcome	Trust	Case	Control	Consortium,	E.M.,	30	
T.Ferreira,	T.J.		Study	PI:	P.D.			31	
MORGAM:	Study	phenotyping:	K.Kuulasmaa,	F.Gianfagna,	A.Wagner,	J.Dallongeville		Genotyping	or	32	
analysis:	M.F.H.,	F.Gianfagna		Study	PI:	J.V.,	J.F.,	A.E.			33	
SardiNIA:	Study	phenotyping:	E.G.L.		Genotyping	or	analysis:	E.G.L.,	O.Meirelles,	S.Sanna,	R.N.,	A.Mulas,	34	
K.V.T.			35	
	25	
NFBC1986:	Study	phenotyping:	M.R.J.,	S.Sebert,	K.H.H.,	A.L.H.		Genotyping	or	analysis:	M.Kaakinen,	1	
A.L.H.		Study	PI:	M.R.J.			2	
DESIR:	Genotyping	or	analysis:	N.B.-N.,	L.Y.,	S.L.		Study	PI:	P.F.,	N.B.-N.,	B.B.			3	
DILGOM:	Study	phenotyping:	S.M.		Genotyping	or	analysis:	K.Kristiansson,	M.P.,	A.S.H.		Study	PI:	V.S.			4	
IMPROVE:	Study	phenotyping:	D.B.		Genotyping	or	analysis:	R.J.S.,	K.G.		Study	PI:	A.Hamsten,	E.Tremoli			5	
HyperGEN:	Study	phenotyping:	S.C.H.,	D.C.R.		Genotyping	or	analysis:	A.C.,	V.P.,	G.B.E.		Study	PI:	S.C.H.			6	
FENLAND	(MetaboChip):	Study	phenotyping:	R.J.F.L.,	J.a.L.,	N.J.W.,	K.K.O.		Genotyping	or	analysis:	7	
R.J.F.L.,	J.a.L.,	N.J.W.,	K.K.O.		Study	PI:	N.J.W.			8	
Whitehall	II:	Study	phenotyping:	M.Kumari		Genotyping	or	analysis:	M.Kumari,	S.Shah,	C.L.		Study	PI:	9	
A.Hingorani,	M.Kivimaki			10	
LURIC:	Genotyping	or	analysis:	M.E.K.,	G.Delgado		Study	PI:	W.M.			11	
MESA:	Study	phenotyping:	W.P.		Genotyping	or	analysis:	W.P.,	X.G.,	J.Y.,	V.D.,	K.D.T.,	J.I.R.,	Y.-D.C.		Study	12	
PI:	W.P.			13	
HUNT2:	Study	phenotyping:	K.Kvaløy,	J.H.,	O.L.H.		Genotyping	or	analysis:	A.U.J.		Study	PI:	K.H.			14	
FINCAVAS:	Genotyping	or	analysis:	T.L.,	L.-P.L.,	K.N.,	M.Kähönen		Study	PI:	T.L.,	M.Kähönen			15	
GenNet:	Study	phenotyping:	R.S.C.,	A.B.W.		Genotyping	or	analysis:	A.C.,	V.P.,	M.X.S.,	D.E.A.,	G.B.E.		16	
Study	PI:	A.C.,	R.S.C.,	A.B.W.			17	
SCARFSHEEP:	Study	phenotyping:	B.G.		Genotyping	or	analysis:	R.J.S.		Study	PI:	A.Hamsten,	U.d.F.			18	
DPS:	Study	phenotyping:	J.L.		Genotyping	or	analysis:	A.U.J.,	P.S.C.		Study	PI:	J.T.,	M.U.			19	
DR's	EXTRA:	Study	phenotyping:	P.K.		Genotyping	or	analysis:	A.U.J.,	M.H.		Study	PI:	R.Rauramaa,	T.A.L.			20	
FIN-D2D	2007:	Genotyping	or	analysis:	A.U.J.,	L.L.B.		Study	PI:	J.Saltevo,	L.M.			21	
METSIM:	Study	phenotyping:	H.M.S.		Genotyping	or	analysis:	A.U.J.,	A.Stančáková		Study	PI:	M.L.,	J.K.			22	
MDC-CVA:	Study	phenotyping:	O.Melander		Genotyping	or	analysis:	O.Melander,	C.F.		Study	PI:	23	
O.Melander			24	
BRIGHT:	Study	phenotyping:	A.F.D.,	M.J.B.,	N.J.S.,	J.M.C.		Genotyping	or	analysis:	T.J.,	P.B.M.		Study	PI:	25	
M.J.C.,	A.F.D.,	M.J.B.,	N.J.S.,	J.M.C.,	P.B.M.			26	
NESDA:	Study	phenotyping:	J.H.S.		Genotyping	or	analysis:	H.Snieder,	I.M.N.		Study	PI:	B.W.P.			27	
EPIC	(MetaboChip):	Study	phenotyping:	R.J.F.L.,	J.a.L.,	N.J.W.		Genotyping	or	analysis:	J.a.L.,	N.J.W.		28	
Study	PI:	N.J.W.,	K.-T.K.			29	
ELY:	Study	phenotyping:	C.L.,	J.a.L.,	N.J.W.		Genotyping	or	analysis:	C.L.,	J.a.L.,	N.J.W.		Study	PI:	N.J.W.			30	
DIAGEN:	Study	phenotyping:	J.G.,	G.M.		Genotyping	or	analysis:	A.U.J.,	G.M.		Study	PI:	P.E.S.,	S.R.B.			31	
GOSH:	Study	phenotyping:	P.K.M.,	N.L.P.		Genotyping	or	analysis:	E.I.,	P.K.M.,	N.L.P.,	T.Fall		Study	PI:	E.I.			32	
Tromsø:	Study	phenotyping:	T.W.		Genotyping	or	analysis:	A.U.J.,	A.J.S.,	N.		Study	PI:	I.N.			33	
ADVANCE:	Study	phenotyping:	T.L.A.,	C.I.		Genotyping	or	analysis:	T.L.A.,	E.L.S.,	T.Q.		Study	PI:	T.L.A.,	34	
T.Q.,	C.I.			35	
ULSAM:	Study	phenotyping:	E.I.,	J.Sundstrom		Genotyping	or	analysis:	E.I.,	N.E.,	J.Sundstrom,	A.-C.S.		36	
Study	PI:	J.Sundstrom			37	
PIVUS:	Study	phenotyping:	L.Lind,	J.Sundstrom		Genotyping	or	analysis:	L.Lind,	N.E.,	J.Sundstrom,	T.A.		38	
Study	PI:	L.Lind,	J.Sundstrom			39	
MRC	NSHD:	Study	phenotyping:	D.K.		Genotyping	or	analysis:	A.Wong,	J.a.L.,	D.K.,	K.K.O.		Study	PI:	D.K.			40	
ASCOT:	Study	phenotyping:	A.Stanton,	N.P.		Genotyping	or	analysis:	T.J.,	M.J.C.,	P.B.M.		Study	PI:	P.S.,	41	
M.J.C.			42	
THISEAS:	Genotyping	or	analysis:	L.S.R.,	S.Kanoni,	E.M.,	G.Kolovou		Study	PI:	G.Dedoussis,	P.D.			43	
PARC:	Study	phenotyping:	R.M.K.		Genotyping	or	analysis:	K.D.T.,	E.Theusch,	J.I.R.,	X.L.,	M.O.G.,	Y.D.I.C.		44	
Study	PI:	R.M.K.			45	
AMC-PAS:	Genotyping	or	analysis:	G.K.H.,	P.D.		Study	PI:	G.K.H.			46	
CARDIOGENICS:	Genotyping	or	analysis:	S.Kanoni,	A.H.G.		Study	PI:	P.D.,	A.H.G.,	J.E.,	N.J.S.,	H.Schunkert			47	
Secondary	analyses	48	
	26	
Allele-specific	FAIRE:	Design	of	secondary	analysis:	A.J.P.S.		Computation	of	secondary	analysis:	A.J.P.S.,	1	
F.D.,	P.H.			2	
ASAP	eQTL:	Design	of	secondary	analysis:	A.F.C.		Computation	of	secondary	analysis:	L.Folkersen,	3	
P.Eriksson			4	
CARDIOGENICS	eQTL:	Computation	of	secondary	analysis:	L.Lataniotis			5	
CM	design:	P.B.M.,	C.N.-C.,	T.J.,	B.F.V.		6	
Comprehensive	literature	review:	Design	of	secondary	analysis:	P.B.M.		Computation	of	secondary	7	
analysis:	K.W.,	P.B.M.			8	
DEPICT:	Design	of	secondary	analysis:	L.Franke,	T.H.P.,	J.N.H.		Computation	of	secondary	analysis:	T.H.P.			9	
DHS	and	methylation	analysis	by	tissue:Design	of	secondary	analysis:	C.J.W.		Computation	of	secondary	10	
analysis:	E.M.S.			11	
DHS	and	methylation	by	cell-line:	Design	of	secondary	analysis:	D.I.C.		Computation	of	secondary	12	
analysis:	D.I.C.,	F.Giulianini			13	
FHS	eSNP:	Design	of	secondary	analysis:	R.Joehanes		Computation	of	secondary	analysis:	R.Joehanes			14	
ICBP	SC:		C.N.-C.,	M.J.C.,	P.B.M.,	A.C.,	K.M.R.,	P.-O'R.,	W.P.,	D.L.,	M.D.T.,	B.M.P.,	A.D.J.,	P.Elliott,	C.M.v.D.,	15	
D.I.C.,	A.V.S.,	M.Bochud,	L.V.W.,	H.Snieder,	G.B.E.			16	
Kidney	eQTL:	Computation	of	secondary	analysis:	H.J.G.,	S.K.K.			17	
MAGENTA:	Design	of	secondary	analysis:	D.I.C.		Computation	of	secondary	analysis:	D.I.C.			18	
Miscellaneous:	Computation	of	secondary	analysis:	H.Warren			19	
MuTHER	eQTL:	Design	of	secondary	analysis:	P.D.		Computation	of	secondary	analysis:	L.Lataniotis,	T.-20	
P.Y.			21	
NESDA	eQTL:	Design	of	secondary	analysis:	R.Jansen		Computation	of	secondary	analysis:	R.Jansen,	A.V.			22	
NTR	eQTL:	Design	of	secondary	analysis:	R.Jansen		Computation	of	secondary	analysis:	R.Jansen,	J.-J.H.		23	
Study	PI:	D.I.B.			24	
eQTL,	EGCUT:Design	of	secondary	analysis:	A.Metspalu		Computation	of	secondary	analysis:	T.E.,	25	
A.Metspalu			26	
eQTL,	Groningen:Design	of	secondary	analysis:	L.Franke		Computation	of	secondary	analysis:	H.J.W.,	27	
L.Franke			28	
Public	eSNP	and	methylation:	Design	of	secondary	analysis:	A.D.J.,	J.D.E.		Computation	of	secondary	29	
analysis:	A.D.J.,	J.D.E.			30	
PubMed	search:	Design	of	secondary	analysis:	G.B.E.		Computation	of	secondary	analysis:	G.B.E.,	L.Lin			31	
WGHS	conditional:	Design	of	secondary	analysis:	D.I.C.		Computation	of	secondary	analysis:	D.I.C.,	32	
F.Giulianini,	L.M.R.		33	
Lookup	of	Cardio-MetaboChip	variants	34	
HEXA:		Genotyping	or	analysis:	Y.J.K.,	Y.K.K.,	Y.-A.S.		Study	PI:	J.-Y.L.			35	
RACe:	Study	phenotyping:	D.Saleheen,	W.Zhao,	A.R.,	A.R.		Genotyping	or	analysis:	W.Zhao,	A.R.,	A.R.		36	
Study	PI:	D.Saleheen			37	
HALST:	Study	phenotyping:	C.A.H.		Genotyping	or	analysis:	J.I.R.,	Y.-D.C.,	C.A.H.,	R.-H.C.,	I.-S.C.		Study	PI:	38	
C.A.H.			39	
CLHNS:	Study	phenotyping:	N.R.L.,	L.S.A.		Genotyping	or	analysis:	Y.W.,	N.R.L.,	L.S.A.		Study	PI:	K.L.M.,	40	
L.S.A.			41	
GxE/Spanish	Town:	Study	phenotyping:	B.O.T.,	C.A.M.,	R.W.		Genotyping	or	analysis:	C.D.P.		Study	PI:	42	
R.S.C.,	C.A.M.,	R.W.,	T.Forrester,	J.N.H.			43	
DRAGON:	Study	phenotyping:	W.-J.L.,	W.H.-H.S.,	K.-W.L.,	I-Te	Lee		Genotyping	or	analysis:	J.I.R.,	Y.-D.C.,	44	
E.K.,	D.A.,	K.D.T.,	X.G.		Study	PI:	W.H.-H.S.			45	
SEY:	Study	phenotyping:	P.B.		Genotyping	or	analysis:	M.Bochud,	G.B.E.,	F.M.		Study	PI:	P.B.,	M.Bochud,	46	
M.Burnier,	F.P.			47	
	27	
TUDR:	Study	phenotyping:	W.H.-H.S.,	I-Te	Lee,	W.-J.L.		Genotyping	or	analysis:	J.I.R.,	Y.-D.C.,	E.K.,	K.D.T.,	1	
X.G.		Study	PI:	W.H.-H.S.			2	
TANDEM:	Study	phenotyping:	P.B.,	M.Bochud		Genotyping	or	analysis:	G.B.E.,	F.M.		Study	PI:	P.B.,	3	
M.Bochud,	M.Burnier,	F.P.	4	
Imputed	genotypes		5	
FHS:	Study	phenotyping:	D.L.		Genotyping	or	analysis:	D.L.		Study	PI:	D.L.			6	
ARIC:	Study	phenotyping:	E.B.		Genotyping	or	analysis:	G.B.E.,	E.B.,	A.C.M.,	A.C.,	S.K.G.		Study	PI:	E.B.,	7	
A.C.			8	
RS:	Genotyping	or	analysis:	G.C.V.,	A.G.U.		Study	PI:	A.Hofman,	A.G.U.,	O.H.F.D.			9	
CoLaus:	Study	phenotyping:	P.V.		Genotyping	or	analysis:	Z.K.		Study	PI:	P.V.			10	
NFBC1966:	Study	phenotyping:	M.R.J.		Genotyping	or	analysis:	P.O.R.		Study	PI:	M.R.J.			11	
SHIP:	Study	phenotyping:	R.Rettig		Genotyping	or	analysis:	A.T.			12	
CHS:	Study	phenotyping:	B.M.P.		Genotyping	or	analysis:	K.M.R.		Study	PI:	B.M.P.			13	
EPIC	(GWAS):	Study	phenotyping:	N.J.W.,	R.J.F.L.,	J.a.L.		Genotyping	or	analysis:	N.J.W.,	J.H.Z.,	J.a.L.		14	
Study	PI:	N.J.W.,	K.-T.K.			15	
SU.VI.MAX:	Study	phenotyping:	S.H.		Genotyping	or	analysis:	S.H.,	P.M.		Study	PI:	P.M.			16	
Amish:	Genotyping	or	analysis:	M.E.M.		Study	PI:	A.Parsa			17	
FENLAND	(GWAS):	Study	phenotyping:	N.J.W.,	J.a.L.,	R.J.F.L.,	K.K.O.		Genotyping	or	analysis:	N.J.W.,	18	
J.a.L.,	R.J.F.L.,	K.K.O.		Study	PI:	N.J.W.			19	
DGI:		Study	phenotyping:	C.N.C.		Genotyping	or	analysis:	C.N.C.,	G.Kosova		Study	PI:	C.N.C.			20	
ERF	(EUROSPAN):		Genotyping	or	analysis:	N.A.		Study	PI:	C.M.v.D.			21	
MIGEN:	Study	phenotyping:	S.Kathiresan,	R.E.		Genotyping	or	analysis:	S.Kathiresan,	R.E.		Design	of	22	
secondary	analysis:	S.Kathiresan,	R.E.			23	
MICROS:	Study	phenotyping:	P.P.P.		Genotyping	or	analysis:	A.A.H.		Study	PI:	A.A.H.,	P.P.P.			24	
FUSION:	Genotyping	or	analysis:	A.U.J.		Study	PI:	M.Boehnke,	F.S.C.,	K.L.M.,	J.Saramies			25	
TwinsUK:	Genotyping	or	analysis:	C.M.		Study	PI:	T.D.S.			26	
PROCARDIS:	Genotyping	or	analysis:	M.Farrall,	A.G.		Study	PI:	M.Farrall			27	
BLSA:	Study	phenotyping:	L.Ferrucci		Genotyping	or	analysis:	T.T.		Study	PI:	L.Ferrucci			28	
ORCADES:	Study	phenotyping:	J.F.W.		Study	PI:	J.F.W.			29	
Croatia-Vis:	Genotyping	or	analysis:	V.V.,	C.H.		Study	PI:	V.V.,	C.H.			30	
NSPHS:	Genotyping	or	analysis:	S.Enroth		Study	PI:	U.G.			31	
InCHIANTI:	Genotyping	or	analysis:	T.T.		Study	PI:	S.Bandinelli			32	
AGES	Reykjavik:	Study	phenotyping:	V.G.		Genotyping	or	analysis:	A.V.S.		Study	PI:	V.G.			33	
Lookup	34	
CARDIoGRAMplusC4D:	Genotyping	or	analysis:	P.D.		Study	PI:	J.Danesh,	H.Schunkert,	T.L.A.,	J.E.,	35	
S.Kathiresan,	R.Roberts,	N.J.S.,	P.D.			36	
CHARGE	cIMT:	Genotyping	or	analysis:	C.O'D.,	J.C.B.			37	
CHARGE	EYE:	Genotyping	or	analysis:	T.Y.W.,	X.S.,	R.A.J.		Study	PI:	T.Y.W.			38	
CHARGE-HF	consortium:	Study	phenotyping:	R.S.V.,	J.F.F.		Genotyping	or	analysis:	H.L.,	J.F.F.		Study	PI:	39	
R.S.V.			40	
CKDGen:	Genotyping	or	analysis:	M.G.,	V.M.			41	
COGENT:		Study	phenotyping:	N.F.,	J.R.		Genotyping	or	analysis:	N.F.,	X.Z.,	B.J.K.,	B.O.T.,	J.R.			42	
EchoGen	consortium:	Study	phenotyping:	R.S.V.,	J.F.F.		Genotyping	or	analysis:	H.L.,	J.F.F.		Study	PI:	43	
R.S.V.			44	
KidneyGen	Consortium:	Study	phenotyping:	J.C.C.,	J.S.K.,	P.Elliott		Genotyping	or	analysis:	W.Zhang,	45	
J.C.C.,	J.S.K.		Study	PI:	J.C.C.,	J.S.K.			46	
MetaStroke:		Genotyping	or	analysis:	S.Bevan,	H.S.M.			47	
NeuroCHARGE:	Genotyping	or	analysis:	M.Fornage,	M.A.I.		Study	PI:	M.A.I.			48	
	28	
PROMIS:	Study	phenotyping:	D.Saleheen,	W.Zhao,	J.Danesh		Genotyping	or	analysis:	W.Zhao		Study	PI:	1	
D.Saleheen			2	
SEED:	Study	phenotyping:	T.Y.W.,	C.-Y.C.		Genotyping	or	analysis:	E.-S.T,	C.-Y.C.,	C.-Y.C.		Study	PI:	C.-Y.C.,	3	
T.Y.W.			4	
UK	Biobank:	BP	group	leaders:	Mark	Caulfield,	P.Elliott		Genotyping	or	analysis:	M.R.B.,	H.Warren,	5	
Claudia	Cabrera,	Evangelos	Evangelou,	He	Gao.	6	
COMPETING	FINANCIAL	INTERESTS	7	
The	authors	declare	competing	financial	interests	(see	corresponding	section	in	the	Supplementary	8	
Note).	9	
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FIGURE	LEGENDS	1	
Figure	1.	Manhattan	plots	for	SBP	and	DBP	from	the	stage	4	Cardio-MetaboChip-wide	meta-analysis.	2	
P	values	(expressed	as	-log10P)	are	plotted	by	physical	genomic	position	labeled	by	chromosome.	SNPs	in	3	
new	loci	(3.5MB	window	around	the	index	SNP),	identified	in	this	study,	are	labeled	in	dark	red	(SBP)	or	4	
dark	blue	(DBP);	SNPs	in	previously	known	loci	are	labeled	in	orange	(SBP)	or	light	blue	(DBP).		The	locus	5	
names	are	indicated.	The	grey	crosses	indicate	genomic	positions	at	which	the	y-axis	was	truncated	6	
(SNPs	with	P	<	10-15).	7	
Figure	2.	Enrichment	of	DNAse	hypersensitive	sites	among	BP	loci	in	different	cell-types.	Enrichment	8	
analyses	of	SBP	or	DBP	associated	loci	according	to	discovery	P	value	using	narrow	peaks	(panel	A)	or	9	
broad	peaks	(panel	B).	SNPs	were	selected	according	to	different	P	value	cutoffs	(x-axis)	and	a	fold	10	
enrichment	of	overlap	with	DNAse	hypersensitive	sites	compared	to	unrelated	GWAS	SNPs	was	11	
calculated	(y-axis)	(see	Supplementary	Note).	The	12	endothelial	cell-lines	are	indicated	in	color	and	for	12	
each	endothelial	cell-type	the	rank	using	the	10-14	P	value	cutoff	is	indicated.	EC	denotes	endothelial	13	
cells.	14	
TABLE	LEGENDS	15	
Table	1.		SBP	and	DBP	association	at	66	loci.	16	
Meta-analysis	 results	 of	 up	 to	342,415	 individuals	of	 European	ancestry	 for	 SBP	and	DBP:	 Established	17	
and	new	 loci	are	grouped	separately.	 	Nearest	genes	are	shown	as	 locus	 labels	but	 this	should	not	be	18	
interpreted	as	support	that	the	causal	gene	is	the	nearest	gene.		The	lead	SNP	with	the	lowest	P	value	19	
for	either	BP	trait	is	shown	as	the	lead	SNP	and	both	SBP	and	DBP	results	are	presented	even	if	both	are	20	
not	genome-wide	significant.		The	SNP	effects	are	shown	according	to	the	effect	in	mm	Hg	per	copy	of	21	
the	coded	allele	 (that	 is	 the	allele	coded	0,	1,	2)	under	an	additive	genetic	model.	“*”	 in	the	 lead	SNP	22	
column	 indicates	 a	 non-synonymous	 coding	 SNP	 (either	 the	 SNP	 itself	 or	 another	 SNP	 in	 r2	 >0.8).	 #	23	
Established	loci	have	smaller	total	sample	sizes	relative	to	novel	loci	(see	Supplementary	Note).	24	
Table	2.		Overview	of	novel	and	known	BP	variant	properties.	25	
Key	characteristics	of	 the	novel	and	established	BP	 loci	 are	 shown.	MAF	and	effect	 size	estimates	are	26	
derived	from	the	Cardio-MetaboChip	data.		Variance	explained	estimates	are	estimated	from	one	large	27	
study	 (Supplementary	Note).	 Novel	 loci	 are	 classified	 as	 previously	 unknown	 to	 be	 linked	 to	 BP	 by	 a	28	
systematic	PubMed	review	of	all	genes	in	a	200kb	window	(Supplementary	Note).	29	
	30	
	32	
Table	3.		Prediction	of	hypertensive	target	organ	damage	by	a	multi-BP	SNP	score.	1	
Shown	 are	 the	 estimated	 effects	 of	 a	 BP	 risk	 score	 comprised	 of	 up	 to	 66	 SNPs	 (see	 column	 “Total	2	
#SNPs”)	 on	 risk	 of	 dichotomous	 outcome	 (as	 odds	 ratios)	 or	 increment	 in	 continuous	 measures	 per	3	
predicted	mmHg	of	the	SBP	or	DBP	score.		The	effect	sizes	are	expressed	as	incremental	change	in	the	4	
phenotype	for	quantitative	traits	and	natural	logarithm	of	the	odds	ratio	for	binary	traits,	per	1	mmHg	5	
predicted	 increase	 in	 SBP	 or	 DBP.	 P	 values	 are	 bolded	 if	 they	 meet	 an	 analysis-wide	 significance	6	
threshold	(<	0.05/18	=	0.0028).	Results	for	all	SNPs	(“all”)	and	for	pruned	results	(“p”)	are	shown.		The	7	
pruned	results	were	obtained	by	iterative	removal	of	SNPs	from	the	risk	score	starting	with	the	SNP	with	8	
lowest	heterogeneity	P	value.	Iterations	to	remove	SNPs	were	continued	until	the	heterogeneity	P value	9	
was	<	0.0028	 (see	Supplementary	Note).	 	The	number	of	SNPs	 removed	when	calculating	 the	pruned	10	
results	 is	 indicated	by	 “#	 SNPs	 rem.”.	 	 The	 results	 per	 individual	 SNP	 can	be	 found	 in	Supplementary	11	
Table	15.		CAD:	coronary	artery	disease,	LV:	left	ventricle,	CKD:	chronic	kidney	disease,	eGFR:	estimated	12	
glomerular	 filtration	 rate,	 cr:	 creatinine,	 cIMT:	 carotid	 intima:	media	 thickness.	 Var.	 type	 denotes	 the	13	
variable	type	and	cont.	for	continuous,	or	dic.	for	dichotomous.	Eth.	=	Ethnicity,	Consort.	=	Consortium,	14	
EUR	=	European	ancestry,	EAS	=	East	Asian	ancestry.	15	
	 	16	
	33	
Table	1.		New	and	known	BP	loci.	1	
Locus	no.	 Locus	name	 Lead	SNP	 Chr	 Position	
(hg19)	
CA	
/NC	
Coded	
allele	
freq	
Traits	 SBP		 		 	DBP	
Effect	 SE	 P	value	 Total	N	 		 Effect	 SE	 P	value	 Total	N#	
NEW	1	 HIVEP3	 rs7515635	 1	 42,408,070	 T/C	 0.468	 SBP	 0.307	 0.0444	 4.81E-12	 340,969	 		 0.1365	 0.0263	 2.05E-07	 340,934	
NEW	2	 PNPT1	 rs1975487	 2	 55,809,054	 A/G	 0.464	 DBP	 -0.2107	 0.045	 2.81E-06	 337,522	 	 -0.1602	 0.0266	 1.75E-09	 337,517	
NEW	3	 FGD5	 rs11128722	 3	 14,958,126	 A/G	 0.563	 SBP	&	DBP	 -0.3103	 0.0469	 3.61E-11	 310,430	 		 -0.1732	 0.0279	 5.16E-10	 310,429	
NEW	4	 ADAMTS9	 rs918466	 3	 64,710,253	 A/G	 0.406	 DBP	 -0.0865	 0.0459	 5.94E-02	 336,671	 	 -0.1819	 0.027	 1.73E-11	 336,653	
NEW	5	 TBC1D1-FLJ13197	 rs2291435	 4	 38,387,395	 T/C	 0.524	 SBP	&	DBP	 -0.3441	 0.0449	 1.90E-14	 331,382	 		 -0.156	 0.0266	 4.26E-09	 331,389	
NEW	6	 TRIM36	 rs10077885	 5	 114,390,121	 A/C	 0.501	 SBP	&	DBP	 -0.284	 0.0444	 1.64E-10	 338,328	 	 -0.1735	 0.0263	 3.99E-11	 338,323	
NEW	7	 CSNK1G3	 rs6891344	 5	 123,136,656	 A/G	 0.819	 DBP	 0.2811	 0.058	 1.24E-06	 338,688	 		 0.2311	 0.0343	 1.58E-11	 338,678	
NEW	8	 CHST12-LFNG	 rs2969070	 7	 2,512,545	 A/G	 0.639	 SBP	&	DBP	 -0.2975	 0.0464	 1.44E-10	 335,991	 	 -0.1821	 0.0274	 2.92E-11	 335,972	
NEW	9	 ZC3HC1	 rs11556924
*	
7	 129,663,496	 T/C	 0.384	 SBP	&	DBP	 -0.2705	 0.0468	 7.64E-09	 325,929	 		 -0.2141	 0.0276	 8.15E-15	 325,963	
NEW	10	 PSMD5	 rs10760117	 9	 123,586,737	 T/G	 0.415	 SBP	 0.283	 0.0457	 6.10E-10	 333,377	 	 0.0999	 0.0269	 2.08E-04	 333,377	
NEW	11	 DBH	 rs6271*	 9	 136,522,274	 T/C	 0.072	 SBP	&	DBP	 -0.5911	 0.0899	 4.89E-11	 306,394	 		 -0.4646	 0.0532	 2.42E-18	 306,463	
NEW	12	 RAPSN,	PSMC3,	SLC39A13	 rs7103648	 11	 47,461,783	 A/G	 0.614	 SBP	&	DBP	 -0.3349	 0.0462	 4.43E-13	 335,614	 	 -0.2409	 0.0272	 9.03E-19	 335,592	
NEW	13	 LRRC10B	 rs751984	 11	 61,278,246	 T/C	 0.879	 SBP	&	DBP	 0.4074	 0.0691	 3.80E-09	 334,583	 		 0.3755	 0.0409	 4.20E-20	 334,586	
NEW	14	 SETBP1	 rs12958173	 18	 42,141,977	 A/C	 0.306	 SBP	&	DBP	 0.3614	 0.0489	 1.43E-13	 331,007	 	 0.1789	 0.0289	 5.87E-10	 331,010	
NEW	15	 INSR	 rs4247374	 19	 7,252,756	 T/C	 0.143	 SBP	&	DBP	 -0.5933	 0.0673	 1.23E-18	 302,458	 		 -0.3852	 0.0396	 2.08E-22	 302,459	
NEW	16	 ELAVL3	 rs17638167	 19	 11,584,818	 T/C	 0.047	 DBP	 -0.4784	 0.1066	 7.13E-06	 333,137	 	 -0.3479	 0.0632	 3.71E-08	 333,107	
NEW	17	 CRYAA-SIK1	 rs12627651	 21	 44,760,603	 A/G	 0.288	 SBP	&	DBP	 0.3905	 0.0513	 2.69E-14	 310,738	 		 0.2037	 0.0301	 1.36E-11	 310,722	
EST	1	 CASZ1	 rs880315	 1	 10,796,866	 T/C	 0.641	 SBP	&	DBP	 -0.475	 0.062	 2.09E-14	 184,226	 	 -0.257	 0.038	 1.34E-11	 184,212	
EST	2	 MTHFR-NPPB	 rs17037390
*	
1	 11,860,843	 A/G	 0.155	 SBP	&	DBP	 -0.908	 0.081	 5.95E-29	 195,493	 		 -0.499	 0.05	 1.20E-23	 195,481	
EST	3	 ST7L-CAPZA1-MOV10	 rs1620668	 1	 113,023,980	 A/G	 0.822	 SBP	&	DBP	 -0.535	 0.076	 1.45E-12	 197,966	 	 -0.285	 0.047	 9.00E-10	 197,948	
EST	4	 MDM4	 rs4245739	 1	 204,518,842	 A/C	 0.737	 DBP	 0.326	 0.068	 1.37E-06	 191,594	 		 0.243	 0.041	 4.63E-09	 191,578	
EST	5	 AGT	 rs2493134*	 1	 230,849,359	 T/C	 0.579	 SBP	&	DBP	 -0.413	 0.058	 9.65E-13	 199,505	 	 -0.275	 0.036	 9.53E-15	 199,502	
EST	6	 KCNK3	 rs2586886	 2	 26,932,031	 T/C	 0.599	 SBP	&	DBP	 -0.404	 0.059	 5.94E-12	 197,269	 		 -0.254	 0.036	 1.92E-12	 197,272	
EST	7	 NCAPH	 rs772178	 2	 96,963,684	 A/G	 0.64	 DBP	 -0.072	 0.061	 2.39E-01	 192,513	 	 -0.208	 0.038	 3.58E-08	 192,501	
EST	8	 FIGN-GRB14	 rs1371182	 2	 165,099,215	 T/C	 0.443	 SBP	&	DBP	 -0.444	 0.058	 1.89E-14	 196,262	 		 -0.252	 0.036	 1.50E-12	 196,240	
EST	9	 HRH1-ATG7	 rs2594992	 3	 11,360,997	 A/C	 0.607	 SBP	 -0.334	 0.06	 2.31E-08	 189,895	 	 -0.136	 0.037	 2.20E-04	 189,854	
EST	10	 SLC4A7	 rs711737	 3	 27,543,655	 A/C	 0.604	 SBP	 0.334	 0.058	 9.93E-09	 200,282	 		 0.17	 0.036	 2.24E-06	 200,260	
EST	11	 ULK4	 rs2272007*	 3	 41,996,136	 T/C	 0.18	 DBP	 -0.11	 0.077	 1.52E-01	 193,915	 	 0.328	 0.047	 3.94E-12	 193,900	
EST	12	 MAP4	 rs6442101*	 3	 48,130,893	 T/C	 0.692	 SBP	&	DBP	 0.396	 0.062	 1.62E-10	 200,543	 		 0.303	 0.038	 1.60E-15	 200,534	
EST	13	 MECOM	 rs6779380	 3	 169,111,915	 T/C	 0.539	 SBP	&	DBP	 -0.439	 0.06	 1.85E-13	 186,535	 	 -0.239	 0.037	 6.87E-11	 186,521	
EST	14	 FGF5	 rs1458038	 4	 81,164,723	 T/C	 0.3	 SBP	&	DBP	 0.659	 0.065	 5.36E-24	 188,136	 		 0.392	 0.04	 7.36E-23	 188,088	
EST	15	 ARHGAP24	 rs17010957	 4	 86,719,165	 T/C	 0.857	 SBP	 -0.498	 0.082	 1.51E-09	 196,325	 	 -0.173	 0.051	 6.63E-04	 196,292	
EST	16	 SLC39A8	 rs13107325
*	
4	 103,188,709	 T/C	 0.07	 SBP	&	DBP	 -0.837	 0.127	 4.69E-11	 175,292	 		 -0.602	 0.078	 1.63E-14	 175,372	
EST	17	 GUCY1A3-GUCY1B3	 rs4691707	 4	 156,441,314	 A/G	 0.652	 SBP	 -0.349	 0.06	 7.10E-09	 198,246	 	 -0.163	 0.037	 1.08E-05	 198,226	
EST	18	 NPR3-C5orf23	 rs12656497	 5	 32,831,939	 T/C	 0.403	 SBP	&	DBP	 -0.487	 0.06	 3.85E-16	 194,831	 		 -0.228	 0.037	 4.73E-10	 194,829	
EST	19	 EBF1	 rs11953630	 5	 157,845,402	 T/C	 0.366	 SBP	&	DBP	 -0.38	 0.065	 3.91E-09	 167,698	 	 -0.23	 0.04	 8.07E-09	 167,708	
EST	20	 HFE	 rs1799945*	 6	 26,091,179	 C/G	 0.857	 SBP	&	DBP	 -0.598	 0.086	 3.28E-12	 185,306	 		 -0.43	 0.053	 3.10E-16	 185,273	
EST	21	 BAT2-BAT5	 rs2187668	 6	 32,605,884	 T/C	 0.126	 DBP	 -0.291	 0.092	 1.60E-03	 189,806	 	 -0.372	 0.057	 4.31E-11	 189,810	
EST	22	 ZNF318-ABCC10	 rs6919440	 6	 43,352,898	 A/G	 0.57	 SBP	 -0.337	 0.058	 4.92E-09	 200,733	 		 -0.125	 0.035	 4.25E-04	 200,730	
EST	23	 RSPO3	 rs1361831	 6	 127,181,089	 T/C	 0.541	 SBP	&	DBP	 -0.482	 0.058	 7.38E-17	 197,027	 	 -0.271	 0.036	 2.34E-14	 197,012	
EST	24	 PLEKHG1	 rs17080093	 6	 150,997,440	 T/C	 0.075	 DBP	 -0.564	 0.111	 3.83E-07	 194,728	 		 -0.411	 0.068	 1.71E-09	 194,734	
EST	25	 HOTTIP-EVX	 rs3735533	 7	 27,245,893	 T/C	 0.081	 SBP	&	DBP	 -0.798	 0.106	 6.48E-14	 197,881	 	 -0.445	 0.065	 1.09E-11	 197,880	
EST	26	 PIK3CG	 rs12705390	 7	 106,410,777	 A/G	 0.227	 SBP	 0.619	 0.069	 2.69E-19	 198,297	 		 0.059	 0.042	 1.63E-01	 198,290	
EST	27	 BLK-GATA4	 rs2898290	 8	 11,433,909	 T/C	 0.491	 SBP	 0.377	 0.058	 8.85E-11	 197,759	 	 0.167	 0.036	 3.17E-06	 197,726	
EST	28	 CACNB2	 rs12243859	 10	 18,740,632	 T/C	 0.326	 SBP	&	DBP	 -0.402	 0.061	 6.13E-11	 199,136	 		 -0.335	 0.038	 8.11E-19	 199,124	
EST	29	 C10orf107	 rs7076398	 10	 63,533,663	 A/T	 0.188	 SBP	&	DBP	 -0.563	 0.076	 1.72E-13	 187,013	 	 -0.409	 0.047	 2.55E-18	 187,024	
EST	30	 SYNPO2L	 rs12247028	 10	 75,410,052	 A/G	 0.611	 SBP	 -0.364	 0.063	 8.16E-09	 180,194	 		 -0.159	 0.039	 3.89E-05	 180,094	
EST	31	 PLCE1	 rs932764*	 10	 95,895,940	 A/G	 0.554	 SBP	&	DBP	 -0.495	 0.059	 6.88E-17	 195,577	 	 -0.224	 0.036	 6.28E-10	 195,547	
EST	32	 CYP17A1-NT5C2	 rs943037	 10	 104,835,919	 T/C	 0.087	 SBP	&	DBP	 -1.133	 0.105	 2.35E-27	 193,818	 		 -0.482	 0.064	 4.48E-14	 193,799	
EST	33	 ADRB1	 rs740746	 10	 115,792,787	 A/G	 0.73	 SBP	&	DBP	 0.486	 0.067	 4.59E-13	 184,835	 	 0.32	 0.041	 8.63E-15	 184,868	
EST	34	 LSP1-TNNT3	 rs592373	 11	 1,890,990	 A/G	 0.64	 SBP	&	DBP	 0.484	 0.063	 2.02E-14	 177,149	 		 0.282	 0.039	 3.61E-13	 177,134	
EST	35	 ADM	 rs1450271	 11	 10,356,115	 T/C	 0.468	 SBP	&	DBP	 0.413	 0.059	 3.40E-12	 191,246	 	 0.199	 0.036	 4.11E-08	 191,221	
EST	36	 PLEKHA7	 rs1156725	 11	 16,307,700	 T/C	 0.804	 SBP	&	DBP	 -0.447	 0.072	 5.65E-10	 200,889	 		 -0.292	 0.044	 3.67E-11	 200,899	
EST	37	 SIPA1	 rs3741378*	 11	 65,408,937	 T/C	 0.137	 SBP	 -0.486	 0.084	 8.04E-09	 194,563	 	 -0.183	 0.052	 4.17E-04	 194,551	
EST	38	 FLJ32810-TMEM133	 rs633185	 11	 100,593,538	 C/G	 0.715	 SBP	&	DBP	 0.522	 0.067	 6.97E-15	 183,845	 		 0.288	 0.041	 2.38E-12	 183,825	
EST	39	 PDE3A	 rs3752728	 12	 20,192,972	 A/G	 0.737	 DBP	 0.331	 0.066	 4.32E-07	 200,440	 		 0.319	 0.04	 2.35E-15	 200,408	
EST	40	 ATP2B1	 rs11105354	 12	 90,026,523	 A/G	 0.84	 SBP	&	DBP	 0.909	 0.081	 3.88E-29	 195,206	 	 0.459	 0.05	 2.61E-20	 195,195	
EST	41	 SH2B3	 rs3184504*	 12	 111,884,608	 T/C	 0.475	 SBP	&	DBP	 0.498	 0.062	 9.97E-16	 177,067	 		 0.362	 0.038	 1.28E-21	 177,122	
EST	42	 TBX5-TBX3	 rs2891546	 12	 115,552,499	 A/G	 0.11	 DBP	 -0.529	 0.1	 1.36E-07	 172,012	 	 -0.38	 0.061	 4.71E-10	 171,980	
EST	43	 CYP1A1-ULK3	 rs936226	 15	 75,069,282	 T/C	 0.722	 SBP	&	DBP	 -0.549	 0.067	 3.06E-16	 187,238	 		 -0.363	 0.041	 1.03E-18	 187,221	
EST	44	 FURIN-FES	 rs2521501	 15	 91,437,388	 A/T	 0.684	 SBP	&	DBP	 -0.639	 0.069	 3.35E-20	 164,272	 	 -0.358	 0.042	 1.85E-17	 164,255	
EST	45	 PLCD3	 rs7213273	 17	 43,155,914	 A/G	 0.658	 SBP	 -0.413	 0.066	 4.71E-10	 164,795	 		 -0.185	 0.041	 7.23E-06	 164,788	
EST	46	 GOSR2	 rs17608766	 17	 45,013,271	 T/C	 0.854	 SBP	 -0.658	 0.083	 2.27E-15	 188,895	 	 -0.218	 0.051	 1.95E-05	 188,928	
EST	47	 ZNF652	 rs12940887	 17	 47,402,807	 T/C	 0.38	 DBP	 0.321	 0.06	 7.06E-08	 192,546	 		 0.261	 0.037	 1.07E-12	 192,524	
EST	48	 JAG1	 rs1327235	 20	 10,969,030	 A/G	 0.542	 SBP	&	DBP	 -0.395	 0.059	 2.23E-11	 192,680	 	 -0.308	 0.036	 1.78E-17	 192,659	
EST	49	 GNAS-EDN3	 rs6026748	 20	 57,745,815	 A/G	 0.125	 SBP	&	DBP	 0.867	 0.089	 3.15E-22	 192,338	 		 0.552	 0.055	 4.86E-24	 192,327	
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Table	2.		Overview	of	novel	and	known	BP	variant	properties.	 1	
	 	 2	
	 17	new	loci	 49	established	loci	 66	loci	
Minor	allele	frequency	
(mean,	range)	
32.1%	[5%-50%]	 28.9%	[7%-49%]	 29.8%	[5%-50%]	
Effect	size	SBP	[mmHg]	
(range,	mean)	
0.09-0.59,	0.34	 0.07-1.13,	0.5	 0.07-1.13,	0.46	
Effect	size	DBP	[mmHg]	
(range,	mean)	
0.1-0.46,	0.23	 0.06-0.60,	0.3	 0.06-0.6,	0.28	
Variance	explained	SBP	 0.52%	 2.95%	 3.46%	
Variance	explained	DBP	 0.58%	 2.78%	 3.36%	
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Table	3.		BP	risk	score	effects	on	disease	outcomes.	 1	
	 	 2	
Phenotype	 Var.	
type	
(cont./
dic.)	
Eth.	 Consort.	 Total	N	
or	no.	
ca/co	
Total	
#SNPs	
SBP_score	 		 DBP_score	
		 		 effect	
(all)	
P	value	
(all)	
het.		P	
value	(all)	
P	value	
(p)	
#	
SNPs		
rem.	
		 effect	
(all)	
P	value	
(all)	
het.	P	
value	(all)	
P	value	
(p)	
#	
SNPs	
rem.	
HEART	 		 		 		 		 		 	 		 	 		 		 		 	 		 	 		 		
CAD		 dich.	 EUR
SAS	
CARDIoG
RAMplus
C4D	
63,746	
/130,681	
61	 1.042	 1.72E-44	 1.75E-25	 4.08E-32	 10	 		 1.069	 1.19E-42	 6.63E-27	 2.2E-38	 10	
heart	failure	 dich.	 EUR	 CHARGE	 2,526	
/18,400		
66	 1.021	 2.77E-02	 1.63E-01	 2.77E-02	 0	 	 1.035	 2.31E-02	 1.70E-01	 2.31E-02	 0	
LV	mass	 cont.	 EUR	 CHARGE	 11,273	 66	 0.480	 6.43E-04	 3.58E-01	 6.43E-04	 0	 		 0.754	 1.23E-03	 3.21E-01	 1.23E-03	 0	
LV	wall	thickness	 cont.	 EUR	 CHARGE	 11,311	 66	 0.004	 4.45E-06	 5.83E-02	 4.45E-06	 0	 		 0.007	 3.19E-06	 6.40E-02	 3.19E-06	 0	
KIDNEY	 		 		 		 		 		 	 	 	 		 		 		 	 	 	 		 		
CKD		 dich.	 EUR	 CHARGE	 6,271	
/68,083	
65	 1.010	 1.37E-01	 1.77E-03	 2.65E-01	 1	 	 1.008	 4.49E-01	 1.25E-03	 7.69E-01	 1	
eGFR	(based	on	cr)		 cont.	 EUR	 CHARGE		 74,354	 65	 0.000	 7.07E-01	 3.12E-05	 3.22E-01	 2	 		 0.000	 9.41E-01	 3.02E-05	 9.65E-01	 2	
eGFR	(based	on	
cystatin)		
cont.	 EUR	 CHARGE	 74,354	 65	 0.001	 9.05E-02	 9.28E-06	 4.11E-01	 1	 		 0.001	 3.30E-01	 5.64E-06	 6.9E-01	 1	
creatinine		 cont.	 EUR	 KidneyGE
N	
23,812	 66	 0.000	 9.42E-01	 6.31E-03	 9.42E-01	 0	 		 0.000	 4.11E-01	 7.16E-03	 4.11E-01	 0	
microalbuminuria		 dich.	 EUR	 CHARGE	 2,499	
/29,081	
65	 0.011	 2.10E-01	 4.79E-02	 2.1E-01	 0	 	 0.023	 1.02E-01	 5.66E-02	 1.02E-02	 0	
urinary	albumin/cr	
ratio	
cont.	 EUR	 CHARGE	 31,580	 65	 0.009	 2.52E-03	 3.02E-04	 0.53E-03	 1	 		 0.015	 2.40E-03	 3.08E-04	 8.31E-03	 1	
STROKE	 		 		 		 		 		 	 	 	 		 		 		 	 	 	 		 		
stroke,	all	subtypes	 dich.	 EUR	 CHARGE	 1,544	
/18,058	
66	 0.056	 6.11E-06	 8.26E-02	 6.11E-06	 0	 	 0.085	 3.79E-05	 4.98E-02	 3.79E-05	 0	
stroke,	ischemic	
subtype	
dich.	 EUR	 CHARGE	 1,164	
/18,438	
66	 0.067	 3.33E-06	 1.75E-01	 3.33E-06	 0	 		 0.096	 5.63E-05	 8.82E-02	 5.63E-05	 0	
stroke,	ischemic	
subtype	
dich.	 EUR	 MetaStro
ke	
11,012	
/40,824	
66	 0.036	 1.69E-10	 4.72E-02	 1.69E-10	 0	 	 0.056	 1.29E-09	 2.51E-02	 1.29E-09	 0	
VASCULATURE	 		 		 		 		 	 	 	 		 		 		 	 	 	 		 		
cIMT	 cont.	 EUR	 CHARGE	 27,610	 66	 0.004	 4.80E-15	 5.06E-08	 7.32E-10	 4	 		 0.005	 4.15E-11	 3.84E-10	 6.2E-07	 5	
EYE	 		 		 		 		 		 	 	 	 		 		 		 	 	 	 		 		
mild	retinop.	 dich.	 EUR	 CHARGE	 1,122	
/18,289	
66	 1.021	 1.37E-01	 6.01E-03	 1.37E-01	 0	 	 1.046	 5.78E-02	 7.81E-03	 5.78E-02	 0	
central	retinal	artery	
caliber	
cont.	 EUR	 CHARGE	 18,576	 66	 0.343	 3.29E-14	 2.56E-06	 2.06E-13	 2	 		 0.570	 3.61E-14	 2.44E-06	 7.05E-13	 3	
mild	retinop.	 dich.	 EAS	 SEED	 289	
/5,419	
66	 1.033	 2.55E-01	 2.42E-01	 2.55E-01	 0	 	 1.087	 8.55E-02	 2.87E-01	 8.55E-02	 0	
central	retinal	artery	
caliber	
cont.	 EAS	 SEED	 6,976	 63	 0.320	 1.39E-04	 9.07E-01	 1.39E-04	 0	 		 0.533	 2.19E-04	 8.91E-01	 2.19E-04	 0	
36 
 
	
ONLINE	METHODS	 1	
Cohorts	contributing	to	systolic	(SBP)	and	diastolic	blood	pressure	(DBP)	analyses	 2	
Studies	contributing	to	BP	association	discovery	including	community-	and	population-based	 3	
collections	as	well	as	studies	of	non-BP	traits,	analyzed	as	case	and	control	samples	separately.		Details	 4	
on	each	of	the	studies	including	study	design	and	BP	measurement	are	provided	in	Supplementary	 5	
Table	1,	genotyping	information	in	Supplementary	Table	2,	and	participant	characteristics	in	 6	
Supplementary	Table	3.		All	participants	provided	written	informed	consent	and	the	studies	were	 7	
approved	by	local	Research	Ethics	Committees	and/or	Institutional	Review	Boards.	 8	
European	ancestry	meta-analysis	 9	
BP	was	measured	using	standardized	protocols	in	all	studies	regardless	of	whether	the	primary	 10	
focus	was	BP	or	another	trait.		We	initially	analyzed	affected	and	unaffected	individuals	from	samples	 11	
selected	as	cases	(e.g.	type	2	diabetes)	or	controls,	separately.		However,	because	sensitivity	analyses	 12	
did	not	reveal	any	significant	difference	in	BP	effect	size	estimates	between	case	and	control	samples	 13	
(data	not	shown),	we	analyzed	all	samples	combined.		When	available,	the	average	of	two	BP	 14	
measurements	was	used	for	association	analyses	(Supplementary	Table	1).	If	an	individual	was	taking	a	 15	
BP-lowering	treatment,	the	underlying	systolic	BP	(SBP)	and	diastolic	BP	(DBP)	were	estimated	by	adding	 16	
15	mmHg	and	10	mmHg,	respectively,	to	the	measured	values,	as	done	in	prior	analyses.	 17	
A	meta-analysis	of	340,934	individuals	of	European	descent	was	undertaken	in	four	stages	with	 18	
subsequent	validation	in	an	independent	cohort.	Because	stage	1	Cardio-MetaboChip	samples	included	 19	
many	SNPs	selected	on	the	basis	of	association	with	BP	in	earlier	GWAS,	we	performed	genomic	control	 20	
using	a	set	of	putative	null	SNPs	based	on	P	>	0.10	in	earlier	GWAS	of	SBP	and	DBP	or	both.		Stage	2	 21	
samples	with	genome-wide	genotyping	used	the	entire	genome-wide	set	of	SNPs	for	genomic	control	 22	
given	the	lack	of	ascertainment.		The	study	design	is	summarized	in	Supplementary	Figure	1,	and	further	 23	
details	are	provided	in	Supplementary	Tables	2-5	and	the	Supplementary	Note.	 24	
Systematic	PubMed	search	+/-	100kb	of	each	newly	discovered	index	SNP	 25	
All	genes	with	any	overlap	with	a	200kb	region	centered	around	each	of	the	17	newly	discovered	 26	
lead	SNPs	were	identified	using	the	UCSC	Genome	Browser.		A	search	term	was	constructed	for	each	 27	
gene	including	the	short	and	long	gene	name	and	the	terms	“blood	pressure”	and	“hypertension”	(e.g.	 28	
for	NPPA	on	chr	1:	“NPPA	OR	natriuretic	peptide	A	AND	(blood	pressure	OR	hypertension)”)	and	the	 29	
search	results	of	each	search	term	from	PubMed	were	individually	reviewed.	 30	
Trait	variance	explained	 31	
The	trait	variance	explained	by	66	lead	SNPs	at	novel	and	known	loci	was	evaluated	in	one	study	 32	
that	contributed	to	the	discovery	effort:	the	Atherosclerosis	Risk	in	Communities	(ARIC)	study.		We	 33	
constructed	a	linear	regression	model	with	all	66	or	the	subset	of	49	known	SNPs	as	a	set	of	predictors	 34	
of	the	BP	residual	after	adjustment	for	covariates	of	the	adjusted	treatment-corrected	BP	phenotype	 35	
(SBP	or	DBP).		The	r2	from	the	regression	model	was	used	as	the	estimate	of	trait	variance	explained.	 36	
European	ancestry	GCTA-COJO	analysis	 37	
To	identify	multiple	distinct	association	signals	at	any	given	BP	locus,	we	undertook	approximate	 38	
conditional	analyses	using	a	model	selection	procedure	implemented	in	the	GCTA-COJO	software	 39	
package44,45.		To	evaluate	the	robustness	of	the	GCTA-COJO	results	to	the	choice	of	reference	data	set,	 40	
model	selection	was	performed	using	the	LD	between	variants	in	separate	analyses	from	two	datasets	of	 41	
European	descent,	both	with	individuals	from	the	UK	with	Cardio-MetaboChip	genotype	data:	GoDARTS	 42	
with	7,006	individuals	and	WTCCC1-T2D/58BC	with	2,947	individuals.		Assuming	that	the	LD	between	 43	
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SNPs	more	than	10	Mb	away	or	on	different	chromosomes	is	zero,	we	undertook	the	GCTA-COJO	step- 1	
wise	model	selection	to	select	SNPs	that	were	conditionally-independently	associated	with	SBP	and	DBP,	 2	
in	turn,	at	a	genome-wide	significance,	given	by	P	<	5×10-8	(Supplementary	Tables	6-8)	using	the	stage	4	 3	
combined	European	GWAS+	Cardio-MetaboChip	meta-analysis.	 4	
Conditional	analyses	in	the	Women’s	Genome	Health	Study	(WGHS)	 5	
Multivariable	 regression	 modeling	 was	 performed	 for	 each	 possible	 combination	 of	 putative	 6	
independent	SNPs	from	a)	model	selection	implemented	in	GCTA-COJO	and	b)	a	comprehensive	manual	 7	
review	of	 the	 literature	 (Supplementary	Table	9).	 	Any	SNP	with	P	 <	5x10-8	 in	a	previous	 reported	BP	 8	
GWAS	was	 considered.	 	A	 total	of	46	SNPs	were	examined	 (Supplementary	Table	10).	 	Genome-wide	 9	
genotyping	data	imputed	to	1000	Genomes	in	the	WGHS	(N	=	23,047)	were	used.		Regression	modeling	 10	
was	performed	in	the	R	statistical	language	(Supplementary	Table	10).	 11	
Fine	mapping	and	determination	of	credible	sets	of	causal	SNPs	 12	
The	GCTA-COJO	and	WGHS	conditional	analyses	identified	multiple	distinct	signals	of	association	at	 13	
multiple	loci	(Supplementary	Tables	6	and	10).		Of	the	24	loci	considered	in	fine-mapping	analyses,	16	 14	
had	no	evidence	for	the	existence	of	multiple	distinct	association	signals,	so	it	is	reasonable	to	assume	 15	
that	there	is	a	single	causal	SNP	and	therefore	the	credible	sets	of	variants	could	be	constructed	using	 16	
the	association	summary	statistics	from	the	unconditional	meta-analyses.		However,	in	the	remaining	 17	
eight	loci,	where	evidence	of	secondary	signals	was	observed	from	GCTA-COJO,	we	performed	 18	
approximate	conditional	analyses	across	the	region	by	conditioning	on	each	index	SNP	(Supplementary	 19	
Table	11).		By	adjusting	for	the	other	index	SNPs	at	the	locus,	we	can	therefore	assume	a	single	variant	is	 20	
driving	each	“conditionally-independent”	association	signal,	and	we	can	construct	the	99%	credible	set	 21	
of	variants	on	the	basis	of	the	approximate	conditional	analysis	from	GCTA-COJO	(Supplementary	 22	
Tables	12-13).		At	five	of	the	eight	loci	with	multiple	distinct	signals	of	association,	one	index	SNP	 23	
mapped	outside	of	the	fine-mapping	region,	so	a	credible	set	could	not	be	constructed.	 24	
eQTL	analysis:	Whole	Blood	 25	
NESDA/NTR:	Whole	blood	eQTL	analyses	were	performed	in	samples	from	the	Netherlands	 26	
Study	of	Depression	and	Anxiety	(NESDA)46	and	the	Netherlands	Twin	Registry	(NTR)47	studies.	RNA	 27	
expression	analysis	was	performed	in	the	statistical	software	R.		The	residuals	resulting	from	the	linear	 28	
regression	analysis	of	the	probe	set	intensity	values	onto	the	covariates	sex,	age,	body	mass	index	 29	
(kg/m2),	smoking	status	coded	as	a	categorical	covariate,	several	technical	covariates,	and	three	 30	
principal	components	were	used.	The	eQTL	effects	were	detected	using	a	linear	mixed	model	approach,	 31	
including	for	each	probe	set	the	expression	level	(normalized,	residualized	and	without	the	first	50	 32	
expression	PCs)	as	dependent	variable;	the	SNP	genotype	values	as	fixed	effects;	and	family	identifier	 33	
and	zygosity	(in	the	case	of	twins)	as	random	effects	to	account	for	family	and	twin	relations48.	 34	
The	eQTL	effects	were	defined	as	cis	when	probe	set–SNP	pairs	were	at	distance	<	1M	base	 35	
pairs.		At	a	FDR	of	0.01	applied	genome-wide,	not	just	for	candidate	SNPs,	the	P	value	threshold	was	 36	
1x10-4	for	the	cis-eQTL	analysis.		For	each	probe	set	that	displayed	a	statistically	significant	association	 37	
with	at	least	one	SNP	located	within	its	cis	region,	we	identified	the	most	significantly	associated	SNP	 38	
and	denoted	this	as	the	top	cis-eQTL	SNP.	See	Supplementary	Note	for	details.	 39	
eQTL	analysis:	Selected	published	eQTL	datasets	 40	
Lead	BP	SNP	and	proxies	(r2	>	0.8)	were	searched	against	a	collected	database	of	expression	SNP	 41	
(eSNP)	results.		The	reported	eSNP	results	met	criteria	for	statistical	thresholds	for	association	with	gene	 42	
transcript	levels	as	described	in	the	original	papers.		The	non-blood	cell	tissue	eQTLs	searched	included	 43	
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aortic	endothelial	cells49,	left	ventricle	of	the	heart	50,	cd14+	monocytes	51	and	the	brain	52.	The	results	 1	
are	presented	in	Supplementary	Tables	14-15.	 2	
Enrichment	analyses:	Analysis	of	cell-specific	DNase	hypersensitivity	sites	(DHSs)	using	an	OR	method	 3	
The	overlap	of	Cardio-MetaboChip	SNPs	with	DHSs	was	examined	using	publicly	available	data	 4	
from	the	Epigenomics	Roadmap	Project	and	ENCODE,	choosing	different	cutoffs	of	Cardio-MetaboChip	P	 5	
values.		The	DHS	mappings	were	available	for	123	mostly	adult	cells	and	tissues	53	(downloaded	from	 6	
The	DHS	mappings	were	specified	as	both	“narrow”	and	“broad”	peaks,	referring	to	reduction	of	the	 7	
experimental	data	to	peak	calls	at	0.1%	and	1.0%	FDR	thresholds,	respectively.		Thus,	the	“narrow”	 8	
peaks	are	largely	nested	within	the	“broad”	peaks.	Experimental	replicates	of	the	DHS	mappings	 9	
(typically	duplicates)	were	also	available	for	the	majority	of	cells	and	tissues.	 10	
	 SNPs	from	the	Cardio-MetaboChip	genome-wide	scan	were	first	clumped	in	PLINK	in	windows	of	 11	
100kb	and	maximum	r2	=	0.1	among	LD	relationships	from	the	1000	Genomes	European	data.		Then,	the	 12	
resulting	index	SNPs	at	each	P	value	threshold	were	tagged	with	r2	=	0.8	in	windows	of	100kb,	again	 13	
using	LD	relationships	in	the	1000	Genomes,	restricted	to	SNPs	with	MAF	>	1%	and	also	present	in	the	 14	
HapMap2	CEU	population.		A	reference	set	of	SNPs	was	constructed	using	the	same	clumping	and	 15	
tagging	procedures	applied	to	GWAS	catalog	SNPs	(available	at	http://www.genome.gov/gwastudies/,	 16	
accessed	3/13/2013)54	with	discovery	P	<	5x10-8	in	European	populations.		A	small	number	of	reference	 17	
SNPs	or	their	proxies	overlapping	the	BP	SNPs	or	their	proxies	were	excluded.		After	LD	pruning	and	 18	
exclusions,	there	were	a	total	of	1,196	reference	SNPs.	For	each	cell	type	and	P	value	threshold,	the	 19	
enrichment	of	SBP	or	DBP	SNPs	(or	their	LD	proxies)	mapping	to	DHSs	was	expressed	as	an	odds	ratio	 20	
(OR)	relative	to	the	GWAS	catalog	reference	SNPs	(or	their	LD	proxies),	using	logistic	mixed	effect	 21	
models	treating	the	replicate	peak	determinations	as	random	effects	(glmer	package	in	R).		The	 22	
significance	of	the	enrichment	ORs	was	derived	from	the	significance	of	beta	coefficients	for	the	main	 23	
effects	in	the	mixed	models	(Figure	2,	Supplementary	Table	16).	 24	
Enrichment	analyses:	Analysis	of	tissue-specific	enrichment	of	BP	variants	and	H3K4me3	sites	 25	
An	analysis	to	test	for	significant	cell-specific	enrichment	in	the	overlap	of	BP	SNPs	(or	their	 26	
proxies)	with	H3K4me3	sites	was	performed	as	described	in	Trynka	et	al,	201355.		The	measure	of	 27	
overlap	is	a	“score”	that	is	constructed	by	dividing	the	height	of	an	H3K4me3	ChIP	signal	in	a	particular	 28	
cell	by	the	distance	between	the	nearest	test	SNP.		The	significance	of	the	scores	(i.e.	P	value)	for	all	 29	
SNPs	was	determined	by	a	permutation	approach	that	compares	the	observed	scores	to	scores	of	SNPs	 30	
with	similar	properties	to	the	test	SNPs,	essentially	in	terms	of	LD	and	proximity	to	genes	 31	
(Supplementary	Note).		The	number	of	permutations	determined	the	number	of	significant	digits	in	the	 32	
P	values	and	we	conducted	10,000	iterations.	Results	are	shown	in	Supplementary	Table	19.	 33	
Enrichment	analyses:	Analysis	of	tissue-specific	DHSs	and	chromatin	states	using	GREGOR	 34	
The	DNase-seq	ENCODE	data	for	all	available	cell	types	were	downloaded	in	the	processed	 35	
“narrowPeak”	format.	The	local	maxima	of	the	tag	density	in	broad,	variable-sized	“hotspot”	regions	of	 36	
chromatin	accessibility	were	thresholded	at	FDR	1%	with	peaks	set	to	a	fixed	width	of	150bp.		Individual	 37	
cell	types	were	further	grouped	into	41	broad	tissue	categories	by	taking	the	union	of	DHSs	for	all	 38	
related	cell	types	and	replicates.	For	each	GWAS	locus,	a	set	of	matched	control	SNPs	was	selected	 39	
based	on	three	criteria:	1)	number	of	variants	in	LD	(r2	>	0.7;	±	8	variants),	2)	MAF	(±	1%),	and	3)	distance	 40	
to	nearest	gene	(±	11,655	bp).	To	calculate	the	distance	to	the	nearest	gene,	the	distance	to	the	5’	 41	
flanking	gene	(start	and	end	position)	and	to	the	3’	flanking	gene	was	calculated	and	the	minimum	of	 42	
these	4	values	was	used.	If	the	SNP	fell	within	the	transcribed	region	of	a	gene,	the	distance	was	0.		The	 43	
probability	that	a	set	of	GWAS	loci	overlap	with	a	regulatory	feature	more	often	than	we	expect	by	 44	
chance	was	estimated.	 45	
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Enrichment	analyses:	FAIRE	analysis	of	BP	variants	in	fine-mapping	regions	in	lymphoblastoid	cell	lines	 1	
FAIRE	analysis	was	performed	on	a	sample	of	20	lymphoblastoid	cell	lines	of	European	origin.	All	 2	
samples	were	genotyped	using	the	Cardio-MetaboChip	genotyping	array,	and	BP	SNPs	and	LD	proxies	(r2	 3	
>	0.8)	at	the	fine	mapping	loci	(N	=	24,	see	Supplementary	Table	23)	were	assessed	to	identify	 4	
heterozygous	imbalance	between	non-treated	and	FAIRE-treated	chromatin.	A	paired	t-test	was	used	to	 5	
compare	the	B	allele	frequency	(BAF)	arising	from	formaldehyde-fixed	chromatin	sheared	by	sonication	 6	
and	DNA	purified	to	the	BAF	when	the	same	chromatin	sample	underwent	FAIRE	to	enrich	for	open	 7	
chromatin.	Three	hundred	and	fifty-seven	Cardio-MetaboChip	BP	SNPs	were	directly	genotyped	across	 8	
the	fine	mapping	regions.	The	Bonferroni-corrected	threshold	of	significance	is	P	<	0.0001	(0.05/357).		 9	
The	results	for	SNPs	with	P	<	0.05	are	reported	in	(Supplementary	Table	23).	FAIRE	results	were	not	 10	
available	for	some	SNPs	with	missing	data	due	to	genotype	failure	or	not	having	>3	heterozygous	 11	
individuals	for	statistical	analysis.	Therefore	there	are	no	results	for	three	lower	frequency	BP	loci	 12	
(SLC39A8,	CYP17A1-NT5C2	and	GNAS-EDN3)	and	for	the	second	signal	at	the	following	loci:	MTHFR- 13	
NPPB	(rs2272803),	MECOM	(rs2242338)	and	HFE	rs1800562).	 14	
Pathway	analyses:	MAGENTA	 15	
MAGENTA	tests	for	enrichment	of	gene	sets	from	a	precompiled	library	derived	from	GO,	KEGG,	 16	
PATHTER,	REACTOME,	INGENUITY,	and	BIOCARTA	was	performed	as	described	by	Segré	et	al,	201056.		 17	
Enrichment	of	significant	gene-wide	P	values	in	gene	sets	is	assessed	by	1)	using	LD	and	distance	criteria	 18	
to	define	the	span	of	each	gene,	2)	selecting	the	smallest	P	value	among	SNPs	mapping	to	the	gene	 19	
span,	and	3)	adjusting	this	P	value	using	a	regression	method	that	accounts	for	the	number	of	SNPs,	the	 20	
LD,	etc.		In	the	second	step,	MAGENTA	examines	the	distribution	of	these	adjusted	P	values	and	defines	 21	
thresholds	for	the	75%ile	and	the	95%ile.		In	the	third	step,	MAGENTA	calculates	an	enrichment	for	each	 22	
gene	set	by	comparing	the	number	of	genes	in	the	gene	set	with	P	value	less	than	either	the	75th	or	 23	
95th	%ile	to	the	number	of	genes	in	the	gene	set	with	P	value	greater	than	either	the	75th	or	95th	%ile,	 24	
and	then	comparing	this	quotient	to	the	same	quotient	among	genes	not	in	the	gene	set.		This	gene-set	 25	
quotient	is	assigned	a	P	value	based	on	reference	to	a	hypergeometric	distribution.		The	results	based	 26	
on	our	analyses	are	indicated	in	Supplementary	Table	21.	 27	
Pathway	analyses:	DEPICT	 28	
We	applied	the	DEPICT	57	analysis	separately	on	genome-wide	significant	loci	from	the	overall	blood	 29	
pressure	(BP)	Cardio-MetaboChip	analysis	including	published	blood	pressure	loci	(see	Supplementary	 30	
Table	22).	SNPs	at	the	HFE	and	BAT2-BAT5	loci	(rs1799945,	rs1800562,	rs2187668,	rs805303,	 31	
rs9268977)	could	not	be	mapped.		As	a	secondary	analysis,	we	additionally	included	associated	loci	(P	<	 32	
1x10-5)	from	the	Cardio-MetaboChip	stage	4	combined	meta-analyses	of	SBP	and	the	DBP.		DEPICT	 33	
assigned	genes	to	associated	regions	if	they	overlapped	or	resided	within	associated	LD	blocks	with	r2	>	 34	
0.5	to	a	given	associated	SNP.	 35	
Literature	review	for	genes	at	the	newly	discovered	loci	 36	
Recognizing	that	the	most	significantly	associated	SNP	at	a	locus	may	not	be	located	in	the	causal	 37	
gene	and	that	the	functional	consequences	of	a	SNP	often	extends	beyond	100kb,	we	conducted	a	 38	
literature	review	of	genes	in	extended	regions	around	newly	discovered	BP	index	SNPs.		The	genes	for	 39	
this	extensive	review	were	identified	by	DEPICT	(Supplementary	Table	22).	 40	
Non-European	meta-analysis	 41	
To	assess	the	association	of	the	66	significant	loci	from	the	European	ancestry	meta-analysis	in	non- 42	
European	ethnicities,	we	obtained	lookup	results	for	the	66	index	SNPs	for	participants	of	South-Asian	 43	
ancestry	(8	datasets,	total	N	=	20,875),	East-Asian	ancestry	(5	datasets,	total	N	=	9,637),	and	African-	and	 44	
40 
 
	
African-American	ancestry	(6	datasets,	total	N	=	33,909).		The	association	analyses	were	all	conducted	 1	
with	the	same	covariates	(age,	age2,	sex,	BMI)	and	treatment	correction	(+15/10	mm	Hg	in	the	presence	 2	
of	any	hypertensive	medication)	as	the	association	analyses	for	the	discovery	effort	in	Europeans.	Tests	 3	
for	heterogeneity	across	effect	estimates	in	European,	South	Asian,	East	Asian	and	African	derived	 4	
samples	were	performed	using	GWAMA58.	 5	
Genetic	risk	score	and	cardiovascular	outcomes	 6	
The	gtx	package	for	the	R	statistical	programming	language	was	used	to	estimate	the	effect	of	the	 7	
SNP-risk	score	on	the	response	variable	in	a	regression	model59.	 8	
9	
41 
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